A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03038100

Recruitment Status : Completed

First Posted : January 31, 2017

Results First Posted : February 17, 2023

Last Update Posted : February 17, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

GOG Foundation

European Network of Gynaecological Oncological Trial Groups (ENGOT)

Information provided by (Responsible Party):

Hoffmann-La Roche

Study Type	Interventional
Study Design	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment
Conditions	Ovarian Cancer Fallopian Tube Cancer Peritoneal Neoplasms
Interventions	Drug: Paclitaxel Drug: Carboplatin Drug: Atezolizumab Drug: Bevacizumab Drug: Atezolizumab Placebo
Enrollment	1301

Participant Flow

Recruitment Details	The study is considered "Completed" because all pre-planned study activities and analyses have been performed.
Pre-assignment Details


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Period Title: Overall Study
Started	650	651
Completed	0	0
Not Completed	650	651
Reason Not Completed
Death	289	272
Lost to Follow-up	9	10
Protocol Deviation	1	4
Withdrawal by Subject	45	51
Study Terminated By Sponsor	305	311
Physician Decision	1	3

Baseline Characteristics

Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab	Total
Arm/Group Description		Participants in the primary tumor-r...	Participants in the primary tumor-r...	Total of all reporting groups
Arm/Group Description		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.	Total of all reporting groups
Overall Number of Baseline Participants		650	651	1301
Baseline Analysis Population Description		[Not Specified]
Baseline Analysis Population Description		[Not Specified]
Age, Continuous Mean (Standard Deviation) Unit of measure: Years
	Number Analyzed	650 participants	651 participants	1301 participants
		59.3 (10.7)	58.9 (10.5)	59.1 (10.6)
Sex: Female, Male Measure Type: Count of Participants Unit of measure: Participants
	Number Analyzed	650 participants	651 participants	1301 participants
	Female	650 100.0%	651 100.0%	1301 100.0%
	Male	0 0.0%	0 0.0%	0 0.0%
Ethnicity (NIH/OMB) Measure Type: Count of Participants Unit of measure: Participants
	Number Analyzed	650 participants	651 participants	1301 participants
	Hispanic or Latino	38 5.8%	39 6.0%	77 5.9%
	Not Hispanic or Latino	598 92.0%	589 90.5%	1187 91.2%
	Unknown or Not Reported	14 2.2%	23 3.5%	37 2.8%
Race (NIH/OMB) Measure Type: Count of Participants Unit of measure: Participants
	Number Analyzed	650 participants	651 participants	1301 participants
	American Indian or Alaska Native	6 0.9%	5 0.8%	11 0.8%
	Asian	155 23.8%	150 23.0%	305 23.4%
	Native Hawaiian or Other Pacific Islander	0 0.0%	2 0.3%	2 0.2%
	Black or African American	13 2.0%	8 1.2%	21 1.6%
	White	461 70.9%	464 71.3%	925 71.1%
	More than one race	0 0.0%	0 0.0%	0 0.0%
	Unknown or Not Reported	15 2.3%	22 3.4%	37 2.8%

Outcome Measures

1.Primary Outcome


Title	Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population
Description	Investigator-assessed PFS is defined as the time from randomization to...
Description	Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.
Time Frame	From randomization until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Intent-to-Treat (ITT) population is defined as all randomized patients, whether or not the assigned study treatment was received.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	650	651
Median (95% Confidence Interval) Unit of Measure: Months
	18.37 (17.22 to 19.75)	19.48 (18.14 to 20.76)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.2785
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.79 to 1.07
	Estimation Comments	[Not Specified]

2.Primary Outcome


Title	PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation
Description	Investigator-assessed PFS is defined as the time from randomization to...
Description	Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.
Time Frame	From randomization until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

PD-L1-positive subpopulation is defined as patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	393	391
Median (95% Confidence Interval) Unit of Measure: Months
	18.50 (16.62 to 21.36)	20.83 (19.06 to 24.21)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0376
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.80
	Confidence Interval	(2-Sided) 95% 0.65 to 0.99
	Estimation Comments	[Not Specified]

3.Primary Outcome


Title	Overall Survival - ITT Population
Description	Overall Survival (OS) is defined as the time from randomization to dea...
Description	Overall Survival (OS) is defined as the time from randomization to death from any cause.
Time Frame	From randomization up to death from any cause (up to approximately 59 months)

Outcome Measure Data

Analysis Population Description

Intent-to-Treat (ITT) population is defined as all randomized patients, whether or not the assigned study treatment was received.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	650	651
Median (95% Confidence Interval) Unit of Measure: Months
	46.59 (45.31 to 49.74)	50.53 ^[1] (46.26 to NA)

[1]

The upper limit of 95% CI was not estimable by Brookmeyer and Crowley method due to insufficient observed events.

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Stratified by: stage and/or surgical status (Stage III vs. Stage IV), ECOG performance status (0 vs. 1 or 2), tumor PD-L1 status (IC0 vs. IC1/2/3), and treatment strategy (adjuvant vs. neoadjuvant).
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.3432
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.78 to 1.09
	Estimation Comments	[Not Specified]

4.Primary Outcome


Title	Overall Survival - PD-L1-Positive Subpopulation
Description	Overall Survival (OS) is defined as the time from randomization to dea...
Description	Overall Survival (OS) is defined as the time from randomization to death from any cause.
Time Frame	From randomization up to death from any cause (up to approximately 59 months)

Outcome Measure Data

Analysis Population Description

PD-L1-positive subpopulation is defined as patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	393	391
Median (95% Confidence Interval) Unit of Measure: Months
	49.15 ^[1] (45.54 to NA)	NA ^[2] (NA to NA)

[1]

The upper limit of 95% CI was not estimable by Brookmeyer and Crowley method due to insufficient observed events.

[2]

67.3% of the participants were censored and the median was not reached.

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Stratified by: stage and/or surgical status (Stage III vs. Stage IV), ECOG performance status (0 vs. 1 or 2) and treatment strategy (adjuvant vs. neoadjuvant).
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1316
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.83
	Confidence Interval	(2-Sided) 95% 0.66 to 1.06
	Estimation Comments	[Not Specified]

5.Secondary Outcome


Title	Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in ITT Population
Description	OR is defined as either a CR or PR as determined by the investigator w...
Description	OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.
Time Frame	From randomization until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Objective Response Rate (ORR) - evaluable population is defined as primary surgery patients in the ITT population with measurable disease at baseline.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	650	651
Measure Type: Number Unit of Measure: Percentage of participants
	88.7	92.8

6.Secondary Outcome


Title	Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in PD-L1-Positive Population
Description	OR is defined as either a CR or PR as determined by the investigator w...
Description	OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.
Time Frame	From randomization until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Objective Response Rate (ORR) - evaluable population is defined as primary surgery patients in the PD-L1-Positive subpopulation with measurable disease at baseline.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	393	391
Measure Type: Number Unit of Measure: Percentage of participants
	89.9	92.3

7.Secondary Outcome


Title	Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in ITT Population
Description	DOR is defined as the time interval from first occurrence of a CR or P...
Description	DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery.
Time Frame	From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Duration of Objective Response (DOR) - evaluable population is defined as patients with an objective response. The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	650	651
Median (95% Confidence Interval) Unit of Measure: Months
	14.06 (13.01 to 16.62)	16.59 (14.52 to 19.09)

8.Secondary Outcome


Title	Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in PD-L1-Positive Population
Description	DOR is defined as the time interval from first occurrence of a CR or P...
Description	DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery.
Time Frame	From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Duration of Objective Response (DOR) - evaluable population is defined as patients with an objective response. The PD-L1-positive subpopulation (defined as patients in the ITT population whose PD-L1 status is IC1/2/3 at the time of randomization) who underwent primary tumor-reductive surgery.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	142	156
Median (95% Confidence Interval) Unit of Measure: Months
	13.44 (12.71 to 19.29)	17.71 (15.01 to 19.61)

9.Secondary Outcome


Title	Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group
Description	Clinically-meaningful improvement defined as a >=10-point decrease ...
Description	Clinically-meaningful improvement defined as a >=10-point decrease from the baseline score in patient-reported abdominal pain or bloating will be assessed using European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Ovarian Cancer Module 28 (EORTC QLQ-OV28) Abdominal/Gastrointestinal Symptom Scale (Items 31 and 31).
Time Frame	From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Outcome Measure Data

Analysis Population Description

Neoadjuvant Group. PRO-evaluable population is defined as patients in the ITT population with a baseline and >=1 post-baseline PRO assessment. The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.


Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		157	152
Measure Type: Number Unit of Measure: Percentage of participants
Abdominal Pain, Presurgical/Surgery	Number Analyzed	142 participants	136 participants
Abdominal Pain, Presurgical/Surgery		54.2	50.7
Abdominal Pain, Cycle 4 Day 1	Number Analyzed	140 participants	133 participants
Abdominal Pain, Cycle 4 Day 1		36.4	32.3
Abdominal Pain, Cycle 6 Day 1	Number Analyzed	131 participants	133 participants
Abdominal Pain, Cycle 6 Day 1		55.0	48.1
Abdominal Pain, Cycle 8 Day 1	Number Analyzed	129 participants	122 participants
Abdominal Pain, Cycle 8 Day 1		64.3	54.1
Abdominal Pain, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
Abdominal Pain, Cycle 12 Day 1		63.1	57.4
Abdominal Pain, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Abdominal Pain, Cycle 16 Day 1		63.5	58.0
Abdominal Pain, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
Abdominal Pain, Cycle 20 Day 1		68.7	48.4
Abdominal Pain, Completion of Treatment/Early Termination Visit	Number Analyzed	143 participants	130 participants
		51.0	51.5
Abdominal Pain, Post-Treatment Follow Up 3 Months	Number Analyzed	96 participants	96 participants
Abdominal Pain, Post-Treatment Follow Up 3 Months		58.3	51.0
Abdominal Pain, Post-Treatment Follow Up 6 Months	Number Analyzed	75 participants	74 participants
Abdominal Pain, Post-Treatment Follow Up 6 Months		61.3	51.4
Abdominal Pain, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Abdominal Pain, Post-Treatment Follow Up 9 Months		60.5	50.0
Abdominal Pain, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Abdominal Pain, Post-Treatment Follow Up 12 Months		70.6	58.3
Abdominal Pain, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Abdominal Pain, Post-Treatment Follow Up 18 Months		100	50
Abdominal Pain, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Abdominal Pain, Post-Treatment Follow Up 24 Months		100	100
Bloating, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Bloating, Presurgical/Surgery		62.7	54.0
Bloating, Cycle 4 Day 1	Number Analyzed	140 participants	132 participants
Bloating, Cycle 4 Day 1		65.0	59.8
Bloating, Cycle 6 Day 1	Number Analyzed	131 participants	133 participants
Bloating, Cycle 6 Day 1		71.0	66.9
Bloating, Cycle 8 Day 1	Number Analyzed	128 participants	123 participants
Bloating, Cycle 8 Day 1		71.9	63.4
Bloating, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
Bloating, Cycle 12 Day 1		68.5	63.4
Bloating, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Bloating, Cycle 16 Day 1		66.7	64.8
Bloating, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
Bloating, Cycle 20 Day 1		66.3	56.5
Bloating, Completion of Treatment/ Early Termination Visit	Number Analyzed	145 participants	130 participants
Bloating, Completion of Treatment/ Early Termination Visit		62.1	58.5
Bloating, Post-Treatment Follow Up 3 Months	Number Analyzed	96 participants	96 participants
Bloating, Post-Treatment Follow Up 3 Months		57.3	53.1
Bloating, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
Bloating, Post-Treatment Follow Up 6 Months		59.2	62.2
Bloating, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Bloating, Post-Treatment Follow Up 9 Months		67.4	63.2
Bloating, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Bloating, Post-Treatment Follow Up 12 Months		47.1	62.5
Bloating, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Bloating, Post-Treatment Follow Up 18 Months		66.7	50.0
Bloating, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Bloating, Post-Treatment Follow Up 24 Months		0	100

10.Secondary Outcome


Title	Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group
Description	Clinically-meaningful improvement in patient-reported function and HRQ...
Description	Clinically-meaningful improvement in patient-reported function and HRQoL during the treatment period, defined as a >=10-point increase from the baseline score on each of the functional (social, emotional, physical, role) and GHS/QoLscales of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Core 30 (EORTC QLQ-C30).
Time Frame	From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Outcome Measure Data

Analysis Population Description

PRO-evaluable population is defined as patients in the ITT population with a baseline and >=1 post-baseline PRO assessment.


Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		157	152
Measure Type: Number Unit of Measure: Percentage of participants
Physical Functioning, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Physical Functioning, Presurgical/Surgery		35.9	33.6
Physical Functioning, Cycle 4 Day 1	Number Analyzed	141 participants	133 participants
Physical Functioning, Cycle 4 Day 1		28.4	18.0
Physical Functioning, Cycle 6 Day 1	Number Analyzed	132 participants	133 participants
Physical Functioning, Cycle 6 Day 1		35.6	25.6
Physical Functioning, Cycle 8 Day 1	Number Analyzed	129 participants	123 participants
Physical Functioning, Cycle 8 Day 1		37.2	36.6
Physical Functioning, Cycle 12 Day 1	Number Analyzed	111 participants	102 participants
Physical Functioning, Cycle 12 Day 1		45.9	43.1
Physical Functioning, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Physical Functioning, Cycle 16 Day 1		42.7	42.0
Physical Functioning, Cycle 20 Day 1	Number Analyzed	83 participants	63 participants
Physical Functioning, Cycle 20 Day 1		41.0	31.7
Physical Functioning, Completion of Treatment/Early Termination Visit	Number Analyzed	144 participants	131 participants
		38.9	34.4
Physical Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	97 participants	97 participants
Physical Functioning, Post-Treatment Follow Up 3 Months		37.1	39.2
Physical Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
Physical Functioning, Post-Treatment Follow Up 6 Months		40.8	39.2
Physical Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Physical Functioning, Post-Treatment Follow Up 9 Months		32.6	50.0
Physical Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Physical Functioning, Post-Treatment Follow Up 12 Months		23.5	37.5
Physical Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Physical Functioning, Post-Treatment Follow Up 18 Months		33.3	50.0
Physical Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Physical Functioning, Post-Treatment Follow Up 24 Months		100	50
Role Functioning, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Role Functioning, Presurgical/Surgery		48.6	40.9
Role Functioning, Cycle 4 Day 1	Number Analyzed	141 participants	133 participants
Role Functioning, Cycle 4 Day 1		38.3	22.6
Role Functioning, Cycle 6 Day 1	Number Analyzed	133 participants	134 participants
Role Functioning, Cycle 6 Day 1		45.9	33.6
Role Functioning, Cycle 8 Day 1	Number Analyzed	129 participants	123 participants
Role Functioning, Cycle 8 Day 1		50.4	39.8
Role Functioning, Cycle 12 Day 1	Number Analyzed	111 participants	102 participants
Role Functioning, Cycle 12 Day 1		55.9	47.1
Role Functioning, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Role Functioning, Cycle 16 Day 1		53.1	46.6
Role Functioning, Cycle 20 Day 1	Number Analyzed	83 participants	63 participants
Role Functioning, Cycle 20 Day 1		56.6	52.4
Role Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	145 participants	131 participants
		46.9	39.7
Role Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	97 participants	97 participants
Role Functioning, Post-Treatment Follow Up 3 Months		49.5	40.2
Role Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
Role Functioning, Post-Treatment Follow Up 6 Months		51.3	48.6
Role Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Role Functioning, Post-Treatment Follow Up 9 Months		53.5	52.6
Role Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Role Functioning, Post-Treatment Follow Up 12 Months		23.5	54.2
Role Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Role Functioning, Post-Treatment Follow Up 18 Months		50.0	50.0
Role Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Role Functioning, Post-Treatment Follow Up 24 Months		0	50
Social Functioning, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Social Functioning, Presurgical/Surgery		32.4	33.6
Social Functioning, Cycle 4 Day 1	Number Analyzed	141 participants	133 participants
Social Functioning, Cycle 4 Day 1		31.2	25.6
Social Functioning, Cycle 6 Day 1	Number Analyzed	133 participants	132 participants
Social Functioning, Cycle 6 Day 1		36.8	33.3
Social Functioning, Cycle 8 Day 1	Number Analyzed	129 participants	122 participants
Social Functioning, Cycle 8 Day 1		40.3	39.3
Social Functioning, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
Social Functioning, Cycle 12 Day 1		39.6	44.6
Social Functioning, Cycle 16 Day 1	Number Analyzed	95 participants	88 participants
Social Functioning, Cycle 16 Day 1		40.0	44.3
Social Functioning, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
Social Functioning, Cycle 20 Day 1		45.8	43.5
Social Functioning, Completion of Treatment/Early Termination	Number Analyzed	144 participants	130 participants
		40.3	41.5
Social Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	96 participants	96 participants
Social Functioning, Post-Treatment Follow Up 3 Months		42.7	44.8
Social Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
Social Functioning, Post-Treatment Follow Up 6 Months		46.1	35.1
Social Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Social Functioning, Post-Treatment Follow Up 9 Months		46.5	47.4
Social Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Social Functioning, Post-Treatment Follow Up 12 Months		29.4	54.2
Social Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Social Functioning, Post-Treatment Follow Up 18 Months		66.7	75.0
Social Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Social Functioning, Post-Treatment Follow Up 24 Months		0	50
Emotional Functioning, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Emotional Functioning, Presurgical/Surgery		31.7	30.7
Emotional Functioning, Cycle 4 Day 1	Number Analyzed	141 participants	132 participants
Emotional Functioning, Cycle 4 Day 1		31.2	35.6
Emotional Functioning, Cycle 6 Day 1	Number Analyzed	133 participants	131 participants
Emotional Functioning, Cycle 6 Day 1		42.1	38.2
Emotional Functioning, Cycle 8 Day 1	Number Analyzed	129 participants	123 participants
Emotional Functioning, Cycle 8 Day 1		39.5	44.7
Emotional Functioning, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
Emotional Functioning, Cycle 12 Day 1		41.4	41.6
Emotional Functioning, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Emotional Functioning, Cycle 16 Day 1		44.8	42.0
Emotional Functioning, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
Emotional Functioning, Cycle 20 Day 1		44.6	32.3
Emotional Functioning, Completion of Treatment/Early Termination Visit	Number Analyzed	145 participants	130 participants
		33.8	33.8
Emotional Functioning, Post-Treatment Follow Up 3 months	Number Analyzed	96 participants	96 participants
Emotional Functioning, Post-Treatment Follow Up 3 months		35.4	33.3
Emotional Functioning, Post-Treatment Follow Up 6 months	Number Analyzed	76 participants	74 participants
Emotional Functioning, Post-Treatment Follow Up 6 months		30.3	33.8
Emotional Functioning, Post-Treatment Follow Up 9 months	Number Analyzed	43 participants	38 participants
Emotional Functioning, Post-Treatment Follow Up 9 months		39.5	34.2
Emotional Functioning, Post-Treatment Follow Up 12 months	Number Analyzed	17 participants	24 participants
Emotional Functioning, Post-Treatment Follow Up 12 months		29.4	29.2
Emotional Functioning, Post-Treatment Follow Up 18 months	Number Analyzed	6 participants	4 participants
Emotional Functioning, Post-Treatment Follow Up 18 months		16.7	50.0
Emotional Functioning, Post-Treatment Follow Up 24 months	Number Analyzed	1 participants	2 participants
Emotional Functioning, Post-Treatment Follow Up 24 months		0	50
GHS/HRQoL, PresurgicalSurgery	Number Analyzed	142 participants	137 participants
GHS/HRQoL, PresurgicalSurgery		44.4	46.7
GHS/HRQoL, Cycle 4 Day 1	Number Analyzed	141 participants	132 participants
GHS/HRQoL, Cycle 4 Day 1		43.3	37.1
GHS/HRQoL, Cycle 6 Day 1	Number Analyzed	133 participants	132 participants
GHS/HRQoL, Cycle 6 Day 1		51.1	47.7
GHS/HRQoL, Cycle 8 Day 1	Number Analyzed	129 participants	122 participants
GHS/HRQoL, Cycle 8 Day 1		55.0	59.0
GHS/HRQoL, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
GHS/HRQoL, Cycle 12 Day 1		60.4	61.4
GHS/HRQoL, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
GHS/HRQoL, Cycle 16 Day 1		53.1	58.0
GHS/HRQoL, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
GHS/HRQoL, Cycle 20 Day 1		59.0	61.3
GHS/HRQoL, Completion of Treatment/ Early Termination Visit	Number Analyzed	145 participants	130 participants
GHS/HRQoL, Completion of Treatment/ Early Termination Visit		46.9	53.1
GHS/HRQoL, Post-Treatment Follow Up 3 Months	Number Analyzed	95 participants	96 participants
GHS/HRQoL, Post-Treatment Follow Up 3 Months		53.7	53.1
GHS/HRQoL, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
GHS/HRQoL, Post-Treatment Follow Up 6 Months		48.7	41.9
GHS/HRQoL, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
GHS/HRQoL, Post-Treatment Follow Up 9 Months		39.5	50.0
GHS/HRQoL, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
GHS/HRQoL, Post-Treatment Follow Up 12 Months		17.6	41.7
GHS/HRQoL, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
GHS/HRQoL, Post-Treatment Follow Up 18 Months		16.7	50.0
GHS/HRQoL, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
GHS/HRQoL, Post-Treatment Follow Up 24 Months		0	50

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9096
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.97
	Confidence Interval	(2-Sided) 95% 0.58 to 1.62
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4662
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.21
	Confidence Interval	(2-Sided) 95% 0.73 to 2.01
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5237
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.85
	Confidence Interval	(2-Sided) 95% 0.51 to 1.40
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3826
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.25
	Confidence Interval	(2-Sided) 95% 0.76 to 2.07
	Estimation Comments	[Not Specified]

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9893
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.56 to 1.76
	Estimation Comments	[Not Specified]

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6892
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.89
	Confidence Interval	(2-Sided) 95% 0.49 to 1.61
	Estimation Comments	[Not Specified]

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1324
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.59
	Confidence Interval	(2-Sided) 95% 0.30 to 1.17
	Estimation Comments	[Not Specified]

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Completion of Treatment/Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9176
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.03
	Confidence Interval	(2-Sided) 95% 0.62 to 1.70
	Estimation Comments	[Not Specified]

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7861
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.50 to 1.68
	Estimation Comments	[Not Specified]

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4539
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.31
	Confidence Interval	(2-Sided) 95% 0.65 to 2.65
	Estimation Comments	[Not Specified]

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4849
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.71
	Confidence Interval	(2-Sided) 95% 0.27 to 1.86
	Estimation Comments	[Not Specified]

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7470
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.79
	Confidence Interval	(2-Sided) 95% 0.19 to 3.34
	Estimation Comments	[Not Specified]

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0896
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	33.33
	Confidence Interval	(2-Sided) 95% -44.86 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -94.30 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7347
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.56 to 1.50
	Estimation Comments	[Not Specified]

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0479
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.56
	Confidence Interval	(2-Sided) 95% 0.32 to 1.00
	Estimation Comments	[Not Specified]

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0712
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.61
	Confidence Interval	(2-Sided) 95% 0.36 to 1.05
	Estimation Comments	[Not Specified]

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8168
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.56 to 1.58
	Estimation Comments	[Not Specified]

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6417
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95% 0.50 to 1.52
	Estimation Comments	[Not Specified]

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8821
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.96
	Confidence Interval	(2-Sided) 95% 0.53 to 1.72
	Estimation Comments	[Not Specified]

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2158
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.64
	Confidence Interval	(2-Sided) 95% 0.32 to 1.30
	Estimation Comments	[Not Specified]

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Completion of Treatment/Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.4762
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95% 0.51 to 1.37
	Estimation Comments	[Not Specified]

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7585
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.10
	Confidence Interval	(2-Sided) 95% 0.61 to 1.96
	Estimation Comments	[Not Specified]

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9985
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.52 to 1.93
	Estimation Comments	[Not Specified]

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1067
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.07
	Confidence Interval	(2-Sided) 95% 0.85 to 5.06
	Estimation Comments	[Not Specified]

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6171
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.42
	Confidence Interval	(2-Sided) 95% 0.36 to 5.61
	Estimation Comments	[Not Specified]

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8084
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.41
	Confidence Interval	(2-Sided) 95% 0.08 to 23.57
	Estimation Comments	[Not Specified]

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3173
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	-50.00
	Confidence Interval	(2-Sided) 95% -100.00 to 94.30
	Estimation Comments	[Not Specified]

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6802
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.10
	Confidence Interval	(2-Sided) 95% 0.69 to 1.77
	Estimation Comments	[Not Specified]

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3470
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.79
	Confidence Interval	(2-Sided) 95% 0.48 to 1.29
	Estimation Comments	[Not Specified]

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5564
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.86
	Confidence Interval	(2-Sided) 95% 0.53 to 1.41
	Estimation Comments	[Not Specified]

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5000
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.19
	Confidence Interval	(2-Sided) 95% 0.72 to 1.99
	Estimation Comments	[Not Specified]

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9778
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.01
	Confidence Interval	(2-Sided) 95% 0.57 to 1.78
	Estimation Comments	[Not Specified]

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6005
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.17
	Confidence Interval	(2-Sided) 95% 0.65 to 2.12
	Estimation Comments	[Not Specified]

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9900
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.50 to 2.00
	Estimation Comments	[Not Specified]

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Completion of Treatment/Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2634
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.32
	Confidence Interval	(2-Sided) 95% 0.81 to 2.15
	Estimation Comments	[Not Specified]

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9640
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95% 0.56 to 1.74
	Estimation Comments	[Not Specified]

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4117
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.76
	Confidence Interval	(2-Sided) 95% 0.40 to 1.46
	Estimation Comments	[Not Specified]

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3505
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.51
	Confidence Interval	(2-Sided) 95% 0.63 to 3.62
	Estimation Comments	[Not Specified]

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2439
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.28
	Confidence Interval	(2-Sided) 95% 0.55 to 9.45
	Estimation Comments	[Not Specified]

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1573
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	33.33
	Confidence Interval	(2-Sided) 95% -44.86 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -94.30 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role Functioning, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1820
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.72
	Confidence Interval	(2-Sided) 95% 0.45 to 1.16
	Estimation Comments	[Not Specified]

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0046
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.47
	Confidence Interval	(2-Sided) 95% 0.28 to 0.80
	Estimation Comments	[Not Specified]

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0361
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.59
	Confidence Interval	(2-Sided) 95% 0.36 to 0.97
	Estimation Comments	[Not Specified]

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0848
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.64
	Confidence Interval	(2-Sided) 95% 0.39 to 1.06
	Estimation Comments	[Not Specified]

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1224
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.64
	Confidence Interval	(2-Sided) 95% 0.37 to 1.13
	Estimation Comments	[Not Specified]

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3127
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.74
	Confidence Interval	(2-Sided) 95% 0.41 to 1.33
	Estimation Comments	[Not Specified]

Statistical Analysis 49

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6065
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95% 0.42 to 1.65
	Estimation Comments	[Not Specified]

Statistical Analysis 50

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2173
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.74
	Confidence Interval	(2-Sided) 95% 0.45 to 1.20
	Estimation Comments	[Not Specified]

Statistical Analysis 51

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1316
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.64
	Confidence Interval	(2-Sided) 95% 0.35 to 1.15
	Estimation Comments	[Not Specified]

Statistical Analysis 52

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7678
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.90
	Confidence Interval	(2-Sided) 95% 0.46 to 1.76
	Estimation Comments	[Not Specified]

Statistical Analysis 53

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7331
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.85
	Confidence Interval	(2-Sided) 95% 0.34 to 2.14
	Estimation Comments	[Not Specified]

Statistical Analysis 54

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1235
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.83
	Confidence Interval	(2-Sided) 95% 0.73 to 10.92
	Estimation Comments	[Not Specified]

Statistical Analysis 55

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	0.00
	Confidence Interval	(2-Sided) 95% -84.09 to 84.09
	Estimation Comments	[Not Specified]

Statistical Analysis 56

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -94.30 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 57

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7869
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.07
	Confidence Interval	(2-Sided) 95% 0.65 to 1.78
	Estimation Comments	[Not Specified]

Statistical Analysis 58

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2502
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.73
	Confidence Interval	(2-Sided) 95% 0.43 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 59

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5066
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95% 0.50 to 1.41
	Estimation Comments	[Not Specified]

Statistical Analysis 60

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8124
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.56 to 1.59
	Estimation Comments	[Not Specified]

Statistical Analysis 61

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4656
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.23
	Confidence Interval	(2-Sided) 95% 0.70 to 2.17
	Estimation Comments	[Not Specified]

Statistical Analysis 62

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6725
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.14
	Confidence Interval	(2-Sided) 95% 0.62 to 2.12
	Estimation Comments	[Not Specified]

Statistical Analysis 63

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5780
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.82
	Confidence Interval	(2-Sided) 95% 0.41 to 1.64
	Estimation Comments	[Not Specified]

Statistical Analysis 64

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Completion of Treatment/Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7611
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.08
	Confidence Interval	(2-Sided) 95% 0.66 to 1.76
	Estimation Comments	[Not Specified]

Statistical Analysis 65

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7588
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.09
	Confidence Interval	(2-Sided) 95% 0.62 to 1.94
	Estimation Comments	[Not Specified]

Statistical Analysis 66

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1428
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.60
	Confidence Interval	(2-Sided) 95% 0.30 to 1.19
	Estimation Comments	[Not Specified]

Statistical Analysis 67

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9802
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95% 0.41 to 2.39
	Estimation Comments	[Not Specified]

Statistical Analysis 68

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1967
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.34
	Confidence Interval	(2-Sided) 95% 0.63 to 8.70
	Estimation Comments	[Not Specified]

Statistical Analysis 69

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4795
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Respnders
	Estimated Value	8.33
	Confidence Interval	(2-Sided) 95% -69.28 to 85.94
	Estimation Comments	[Not Specified]

Statistical Analysis 70

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -94.30 to 100.00
	Estimation Comments	[Not Specified]

11.Secondary Outcome


Title	Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group
Description	Percentage of participants with clinical improvement, defined as >=...
Description	Percentage of participants with clinical improvement, defined as >= 10-point increase from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Time Frame	From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Outcome Measure Data

Analysis Population Description

PRO-evaluable population is defined as patients in the ITT population with a baseline and >=1 post-baseline PRO assessment.


Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		473	473
Measure Type: Number Unit of Measure: Percentage of participants
Physical Functioning, Cycle 3 Day 1	Number Analyzed	456 participants	444 participants
Physical Functioning, Cycle 3 Day 1		22.6	19.8
Physical Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	423 participants
Physical Functioning, Cycle 5 Day 1		23.7	21.3
Physical Functioning, Cycle 8 Day 1	Number Analyzed	414 participants	403 participants
Physical Functioning, Cycle 8 Day 1		28.7	27.0
Physical Functioning, Cycle 12 Day 1	Number Analyzed	378 participants	358 participants
Physical Functioning, Cycle 12 Day 1		35.4	32.4
Physical Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Physical Functioning, Cycle 16 Day 1		32.1	34.3
Physical Functioning, Cycle 20 Day 1	Number Analyzed	253 participants	234 participants
Physical Functioning, Cycle 20 Day 1		34.8	32.5
Physical Functioning, Completion of Treatment/Early Termination Visit	Number Analyzed	370 participants	366 participants
		32.4	30.3
Physical Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	235 participants	236 participants
Physical Functioning, Post-Treatment Follow Up 3 Months		35.7	28.4
Physical Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	147 participants	164 participants
Physical Functioning, Post-Treatment Follow Up 6 Months		32.7	31.1
Physical Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Physical Functioning, Post-Treatment Follow Up 9 Months		34.5	27.6
Physical Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Physical Functioning, Post-Treatment Follow Up 12 Months		37.8	24.1
Physical Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Physical Functioning, Post-Treatment Follow Up 18 Months		42.9	18.8
Physical Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Physical Functioning, Post-Treatment Follow Up 24 Months		0	16.7
Role Functioning, Cycle 3 Day 1	Number Analyzed	455 participants	443 participants
Role Functioning, Cycle 3 Day 1		42.6	40.9
Role Functioning, Cycle 5 Day 1	Number Analyzed	438 participants	422 participants
Role Functioning, Cycle 5 Day 1		42.9	38.9
Role Functioning, Cycle 8 Day 1	Number Analyzed	413 participants	401 participants
Role Functioning, Cycle 8 Day 1		47.5	45.9
Role Functioning, Cycle 12 Day 1	Number Analyzed	377 participants	358 participants
Role Functioning, Cycle 12 Day 1		50.1	50.6
Role Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	311 participants
Role Functioning, Cycle 16 Day 1		52.0	50.8
Role Functioning, Cycle 20 Day 1	Number Analyzed	253 participants	233 participants
Role Functioning, Cycle 20 Day 1		53.8	51.5
Role Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	370 participants	367 participants
		48.4	46.6
Role Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	235 participants	236 participants
Role Functioning, Post-Treatment Follow Up 3 Months		54.0	45.3
Role Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	147 participants	164 participants
Role Functioning, Post-Treatment Follow Up 6 Months		55.1	43.9
Role Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Role Functioning, Post-Treatment Follow Up 9 Months		57.1	38.8
Role Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Role Functioning, Post-Treatment Follow Up 12 Months		60	27.6
Role Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Role Functioning, Post-Treatment Follow Up 18 Months		50	43.8
Role Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Role Functioning, Post-Treatment Follow Up 24 Months		50	16.7
Social Functioning, Cycle 3 Day 1	Number Analyzed	455 participants	442 participants
Social Functioning, Cycle 3 Day 1		30.1	31.4
Social Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
Social Functioning, Cycle 5 Day 1		32.6	32.0
Social Functioning, Cycle 8 Day 1	Number Analyzed	413 participants	403 participants
Social Functioning, Cycle 8 Day 1		37.8	38.7
Social Functioning, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
Social Functioning, Cycle 12 Day 1		42.6	41.2
Social Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Social Functioning, Cycle 16 Day 1		43.5	48.7
Social Functioning, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
Social Functioning, Cycle 20 Day 1		45.6	50.0
Social Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	367 participants	367 participants
		40.6	40.1
Social Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
Social Functioning, Post-Treatment Follow Up 3 Months		42.7	41.1
Social Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
Social Functioning, Post-Treatment Follow Up 6 Months		43.2	34.1
Social Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Social Functioning, Post-Treatment Follow Up 9 Months		50.0	36.7
Social Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Social Functioning, Post-Treatment Follow Up 12 Months		62.2	36.2
Social Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Social Functioning, Post-Treatment Follow Up 18 Months		57.1	43.8
Social Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Social Functioning, Post-Treatment Follow Up 24 Months		100	50
Emotional Functioning, Cycle 3 Day 1	Number Analyzed	454 participants	443 participants
Emotional Functioning, Cycle 3 Day 1		29.7	28.4
Emotional Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
Emotional Functioning, Cycle 5 Day 1		30.3	30.3
Emotional Functioning, Cycle 8 Day 1	Number Analyzed	412 participants	403 participants
Emotional Functioning, Cycle 8 Day 1		32.3	33.0
Emotional Functioning, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
Emotional Functioning, Cycle 12 Day 1		34.6	36.1
Emotional Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Emotional Functioning, Cycle 16 Day 1		31.8	35.9
Emotional Functioning, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
Emotional Functioning, Cycle 20 Day 1		35.3	36.8
Emotional Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	368 participants	367 participants
		27.7	28.6
Emotional Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
Emotional Functioning, Post-Treatment Follow Up 3 Months		29.1	27.5
Emotional Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
Emotional Functioning, Post-Treatment Follow Up 6 Months		30.4	37.8
Emotional Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Emotional Functioning, Post-Treatment Follow Up 9 Months		38.1	33.7
Emotional Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Emotional Functioning, Post-Treatment Follow Up 12 Months		44.4	34.5
Emotional Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Emotional Functioning, Post-Treatment Follow Up 18 Months		42.9	31.3
Emotional Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Emotional Functioning, Post-Treatment Follow Up 24 Months		50.0	16.7
GHS/OoL, Cycle 3 Day 1	Number Analyzed	455 participants	443 participants
GHS/OoL, Cycle 3 Day 1		32.3	34.5
GHS/OoL, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
GHS/OoL, Cycle 5 Day 1		33.0	31.0
GHS/OoL, Cycle 8 Day 1	Number Analyzed	413 participants	403 participants
GHS/OoL, Cycle 8 Day 1		39.5	38.7
GHS/OoL, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
GHS/OoL, Cycle 12 Day 1		41.5	43.4
GHS/OoL, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
GHS/OoL, Cycle 16 Day 1		42.9	42.9
GHS/OoL, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
GHS/OoL, Cycle 20 Day 1		42.5	46.2
GHS/OoL, Completion of Treatment/ Early Termination Visit	Number Analyzed	368 participants	367 participants
GHS/OoL, Completion of Treatment/ Early Termination Visit		38.0	34.9
GHS/OoL, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
GHS/OoL, Post-Treatment Follow Up 3 Months		40.6	38.6
GHS/OoL, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
GHS/OoL, Post-Treatment Follow Up 6 Months		39.2	34.1
GHS/OoL, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
GHS/OoL, Post-Treatment Follow Up 9 Months		39.3	35.7
GHS/OoL, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
GHS/OoL, Post-Treatment Follow Up 12 Months		40.0	32.8
GHS/OoL, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
GHS/OoL, Post-Treatment Follow Up 18 Months		42.9	18.8
GHS/OoL, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
GHS/OoL, Post-Treatment Follow Up 24 Months		100	33.3

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6651
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.70 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9927
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.75 to 1.34
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8209
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.03
	Confidence Interval	(2-Sided) 95% 0.77 to 1.39
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6507
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.07
	Confidence Interval	(2-Sided) 95% 0.79 to 1.45
	Estimation Comments	[Not Specified]

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2596
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.21
	Confidence Interval	(2-Sided) 95% 0.87 to 1.67
	Estimation Comments	[Not Specified]

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6532
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.09
	Confidence Interval	(2-Sided) 95% 0.75 to 1.58
	Estimation Comments	[Not Specified]

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Completion Of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7592
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.05
	Confidence Interval	(2-Sided) 95% 0.76 to 1.45
	Estimation Comments	[Not Specified]

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7424
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.93
	Confidence Interval	(2-Sided) 95% 0.62 to 1.40
	Estimation Comments	[Not Specified]

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1912
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.37
	Confidence Interval	(2-Sided) 95% 0.85 to 2.19
	Estimation Comments	[Not Specified]

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5526
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.83
	Confidence Interval	(2-Sided) 95% 0.45 to 1.53
	Estimation Comments	[Not Specified]

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3609
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.69
	Confidence Interval	(2-Sided) 95% 0.32 to 1.52
	Estimation Comments	[Not Specified]

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7527
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.80
	Confidence Interval	(2-Sided) 95% 0.20 to 3.23
	Estimation Comments	[Not Specified]

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	-33.33
	Confidence Interval	(2-Sided) 95% -100.00 to 75.44
	Estimation Comments	[Not Specified]

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3177
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.85
	Confidence Interval	(2-Sided) 95% 0.62 to 1.17
	Estimation Comments	[Not Specified]

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4184
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95% 0.63 to 1.21
	Estimation Comments	[Not Specified]

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5710
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.91
	Confidence Interval	(2-Sided) 95% 0.67 to 1.24
	Estimation Comments	[Not Specified]

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3973
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95% 0.65 to 1.19
	Estimation Comments	[Not Specified]

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5163
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.12
	Confidence Interval	(2-Sided) 95% 0.80 to 1.55
	Estimation Comments	[Not Specified]

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6897
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.93
	Confidence Interval	(2-Sided) 95% 0.64 to 1.35
	Estimation Comments	[Not Specified]

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Completion Of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5735
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.91
	Confidence Interval	(2-Sided) 95% 0.67 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1414
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.75
	Confidence Interval	(2-Sided) 95% 0.50 to 1.10
	Estimation Comments	[Not Specified]

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8655
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.96
	Confidence Interval	(2-Sided) 95% 0.59 to 1.55
	Estimation Comments	[Not Specified]

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3017
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.72
	Confidence Interval	(2-Sided) 95% 0.38 to 1.35
	Estimation Comments	[Not Specified]

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2325
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.60
	Confidence Interval	(2-Sided) 95% 0.26 to 1.39
	Estimation Comments	[Not Specified]

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1717
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.33
	Confidence Interval	(2-Sided) 95% 0.06 to 1.69
	Estimation Comments	[Not Specified]

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analsyis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	16.67
	Confidence Interval	(2-Sided) 95% -46.49 to 79.82
	Estimation Comments	[Not Specified]

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4745
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.11
	Confidence Interval	(2-Sided) 95% 0.84 to 1.46
	Estimation Comments	[Not Specified]

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5499
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.69 to 1.22
	Estimation Comments	[Not Specified]

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8436
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.97
	Confidence Interval	(2-Sided) 95% 0.73 to 1.29
	Estimation Comments	[Not Specified]

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5798
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.09
	Confidence Interval	(2-Sided) 95% 0.81 to 1.46
	Estimation Comments	[Not Specified]

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9094
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.02
	Confidence Interval	(2-Sided) 95% 0.74 to 1.39
	Estimation Comments	[Not Specified]

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4006
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.17
	Confidence Interval	(2-Sided) 95% 0.81 to 1.67
	Estimation Comments	[Not Specified]

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4024
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95% 0.65 to 1.19
	Estimation Comments	[Not Specified]

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8796
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.97
	Confidence Interval	(2-Sided) 95% 0.67 to 1.41
	Estimation Comments	[Not Specified]

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4350
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.83
	Confidence Interval	(2-Sided) 95% 0.53 to 1.32
	Estimation Comments	[Not Specified]

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6225
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.86
	Confidence Interval	(2-Sided) 95% 0.47 to 1.56
	Estimation Comments	[Not Specified]

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5775
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.80
	Confidence Interval	(2-Sided) 95% 0.36 to 1.77
	Estimation Comments	[Not Specified]

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2343
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.37
	Confidence Interval	(2-Sided) 95% 0.07 to 1.94
	Estimation Comments	[Not Specified]

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0833
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	-66.67
	Confidence Interval	(2-Sided) 95% -100.00 to 4.39
	Estimation Comments	[Not Specified]

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Superiority

Statistical Test of Hypothesis	P-Value	0.6012
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.93
	Confidence Interval	(2-Sided) 95% 0.71 to 1.21
	Estimation Comments	[Not Specified]

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2291
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.85
	Confidence Interval	(2-Sided) 95% 0.65 to 1.11
	Estimation Comments	[Not Specified]

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6574
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.71 to 1.24
	Estimation Comments	[Not Specified]

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9217
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.01
	Confidence Interval	(2-Sided) 95% 0.76 to 1.35
	Estimation Comments	[Not Specified]

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7693
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.95
	Confidence Interval	(2-Sided) 95% 0.70 to 1.30
	Estimation Comments	[Not Specified]

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6470
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.64 to 1.31
	Estimation Comments	[Not Specified]

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Completion Of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6391
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.93
	Confidence Interval	(2-Sided) 95% 0.70 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0892
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.73
	Confidence Interval	(2-Sided) 95% 0.51 to 1.05
	Estimation Comments	[Not Specified]

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0550
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.65
	Confidence Interval	(2-Sided) 95% 0.41 to 1.01
	Estimation Comments	[Not Specified]

Statistical Analysis 49

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0168
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.49
	Confidence Interval	(2-Sided) 95% 0.27 to 0.88
	Estimation Comments	[Not Specified]

Statistical Analysis 50

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0021
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.29
	Confidence Interval	(2-Sided) 95% 0.13 to 0.65
	Estimation Comments	[Not Specified]

Statistical Analysis 51

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7817
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.80
	Confidence Interval	(2-Sided) 95% 0.17 to 3.80
	Estimation Comments	[Not Specified]

Statistical Analysis 52

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	-33.33
	Confidence Interval	(2-Sided) 95% -100.00 to 75.44
	Estimation Comments	[Not Specified]

Statistical Analysis 53

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6646
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.06
	Confidence Interval	(2-Sided) 95% 0.80 to 1.41
	Estimation Comments	[Not Specified]

Statistical Analysis 54

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8677
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.98
	Confidence Interval	(2-Sided) 95% 0.73 to 1.30
	Estimation Comments	[Not Specified]

Statistical Analysis 55

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7670
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.04
	Confidence Interval	(2-Sided) 95% 0.79 to 1.38
	Estimation Comments	[Not Specified]

Statistical Analysis 56

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.7487
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.95
	Confidence Interval	(2-Sided) 95% 0.71 to 1.28
	Estimation Comments	[Not Specified]

Statistical Analysis 57

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1882
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.23
	Confidence Interval	(2-Sided) 95% 0.90 to 1.68
	Estimation Comments	[Not Specified]

Statistical Analysis 58

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.3015
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.21
	Confidence Interval	(2-Sided) 95% 0.84 to 1.72
	Estimation Comments	[Not Specified]

Statistical Analysis 59

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9059
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.98
	Confidence Interval	(2-Sided) 95% 0.73 to 1.32
	Estimation Comments	[Not Specified]

Statistical Analysis 60

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.7125
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.93
	Confidence Interval	(2-Sided) 95% 0.65 to 1.35
	Estimation Comments	[Not Specified]

Statistical Analysis 61

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0947
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.68
	Confidence Interval	(2-Sided) 95% 0.43 to 1.07
	Estimation Comments	[Not Specified]

Statistical Analysis 62

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0686
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.58
	Confidence Interval	(2-Sided) 95% 0.32 to 1.05
	Estimation Comments	[Not Specified]

Statistical Analysis 63

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0175
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.39
	Confidence Interval	(2-Sided) 95% 0.17 to 0.86
	Estimation Comments	[Not Specified]

Statistical Analysis 64

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3376
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.46
	Confidence Interval	(2-Sided) 95% 0.09 to 2.30
	Estimation Comments	[Not Specified]

Statistical Analysis 65

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.5637
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	-50.00
	Confidence Interval	(2-Sided) 95% -100.00 to 23.34
	Estimation Comments	[Not Specified]

12.Secondary Outcome


Title	Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group
Description	Percentage of participants who remain stable defined as changes within...
Description	Percentage of participants who remain stable defined as changes within 10 points from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Time Frame	From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Outcome Measure Data

Analysis Population Description

PRO-evaluable population is defined as patients in the ITT population with a baseline and >=1 post-baseline PRO assessment.


Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		473	473
Measure Type: Number Unit of Measure: Percentage of participants
Physical Functioning, Cycle 3 Day 1	Number Analyzed	456 participants	444 participants
Physical Functioning, Cycle 3 Day 1		53.1	56.1
Physical Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	423 participants
Physical Functioning, Cycle 5 Day 1		49.0	50.1
Physical Functioning, Cycle 8 Day 1	Number Analyzed	414 participants	403 participants
Physical Functioning, Cycle 8 Day 1		47.8	49.4
Physical Functioning, Cycle 12 Day 1	Number Analyzed	378 participants	358 participants
Physical Functioning, Cycle 12 Day 1		47.1	51.1
Physical Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Physical Functioning, Cycle 16 Day 1		50.5	48.7
Physical Functioning, Cycle 20 Day 1	Number Analyzed	253 participants	234 participants
Physical Functioning, Cycle 20 Day 1		46.6	50.9
Physical Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	370 participants	366 participants
		46.8	44.5
Physical Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	235 participants	236 participants
Physical Functioning, Post-Treatment Follow Up 3 Months		41.3	47.9
Physical Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	147 participants	164 participants
Physical Functioning, Post-Treatment Follow Up 6 Months		42.2	43.9
Physical Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Physical Functioning, Post-Treatment Follow Up 9 Months		46.4	46.9
Physical Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Physical Functioning, Post-Treatment Follow Up 12 Months		44.4	50.0
Physical Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Physical Functioning, Post-Treatment Follow Up 18 Months		35.7	56.3
Physical Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Physical Functioning, Post-Treatment Follow Up 24 Months		100	33.3
Role Functioning, Cycle 3 Day 1	Number Analyzed	455 participants	443 participants
Role Functioning, Cycle 3 Day 1		35.8	30.9
Role Functioning, Cycle 5 Day 1	Number Analyzed	438 participants	422 participants
Role Functioning, Cycle 5 Day 1		30.1	33.6
Role Functioning, Cycle 8 Day 1	Number Analyzed	413 participants	401 participants
Role Functioning, Cycle 8 Day 1		31.2	30.9
Role Functioning, Cycle 12 Day 1	Number Analyzed	377 participants	358 participants
Role Functioning, Cycle 12 Day 1		32.9	32.1
Role Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	311 participants
Role Functioning, Cycle 16 Day 1		27.6	33.4
Role Functioning, Cycle 20 Day 1	Number Analyzed	253 participants	233 participants
Role Functioning, Cycle 20 Day 1		27.3	34.8
Role Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	370 participants	367 participants
		28.6	28.6
Role Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	235 participants	236 participants
Role Functioning, Post-Treatment Follow Up 3 Months		25.1	27.1
Role Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	147 participants	164 participants
Role Functioning, Post-Treatment Follow Up 6 Months		24.5	29.9
Role Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Role Functioning, Post-Treatment Follow Up 9 Months		23.8	34.7
Role Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Role Functioning, Post-Treatment Follow Up 12 Months		33.3	34.5
Role Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Role Functioning, Post-Treatment Follow Up 18 Months		42.9	25.0
Role Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Role Functioning, Post-Treatment Follow Up 24 Months		50	66.7
Social Functioning, Cycle 3 Day 1	Number Analyzed	455 participants	442 participants
Social Functioning, Cycle 3 Day 1		40.7	36.7
Social Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
Social Functioning, Cycle 5 Day 1		37.6	36.7
Social Functioning, Cycle 8 Day 1	Number Analyzed	413 participants	403 participants
Social Functioning, Cycle 8 Day 1		40.2	35.2
Social Functioning, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
Social Functioning, Cycle 12 Day 1		38.3	39.2
Social Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Social Functioning, Cycle 16 Day 1		36.6	33.3
Social Functioning, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
Social Functioning, Cycle 20 Day 1		34.1	33.8
Social Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	367 participants	367 participants
		31.9	31.1
Social Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
Social Functioning, Post-Treatment Follow Up 3 Months		30.3	32.6
Social Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
Social Functioning, Post-Treatment Follow Up 6 Months		33.8	34.8
Social Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Social Functioning, Post-Treatment Follow Up 9 Months		27.4	30.6
Social Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Social Functioning, Post-Treatment Follow Up 12 Months		28.9	25.9
Social Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Social Functioning, Post-Treatment Follow Up 18 Months		28.6	18.8
Social Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Social Functioning, Post-Treatment Follow Up 24 Months		0	16.7
Emotional Functioning, Cycle 3 Day 1	Number Analyzed	454 participants	443 participants
Emotional Functioning, Cycle 3 Day 1		57.5	57.3
Emotional Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
Emotional Functioning, Cycle 5 Day 1		52.4	53.6
Emotional Functioning, Cycle 8 Day 1	Number Analyzed	412 participants	403 participants
Emotional Functioning, Cycle 8 Day 1		53.2	54.6
Emotional Functioning, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
Emotional Functioning, Cycle 12 Day 1		53.2	50.1
Emotional Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Emotional Functioning, Cycle 16 Day 1		55.0	51.3
Emotional Functioning, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
Emotional Functioning, Cycle 20 Day 1		49.2	52.1
Emotional Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	368 participants	367 participants
		53.0	51.8
Emotional Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
Emotional Functioning, Post-Treatment Follow Up 3 Months		51.3	55.5
Emotional Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
Emotional Functioning, Post-Treatment Follow Up 6 Months		48.6	47.6
Emotional Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Emotional Functioning, Post-Treatment Follow Up 9 Months		53.6	48.0
Emotional Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Emotional Functioning, Post-Treatment Follow Up 12 Months		46.7	43.1
Emotional Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Emotional Functioning, Post-Treatment Follow Up 18 Months		50.0	37.5
Emotional Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Emotional Functioning, Post-Treatment Follow Up 24 Months		50.0	16.7
GHS/OoL, Cycle 3 Day 1	Number Analyzed	455 participants	443 participants
GHS/OoL, Cycle 3 Day 1		43.3	42.2
GHS/OoL, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
GHS/OoL, Cycle 5 Day 1		42.6	44.8
GHS/OoL, Cycle 8 Day 1	Number Analyzed	413 participants	403 participants
GHS/OoL, Cycle 8 Day 1		39.0	42.9
GHS/OoL, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
GHS/OoL, Cycle 12 Day 1		40.7	42.9
GHS/OoL, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
GHS/OoL, Cycle 16 Day 1		38.4	43.3
GHS/OoL, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
GHS/OoL, Cycle 20 Day 1		36.9	42.3
GHS/OoL, Completion of Treatment/ Early Termination Visit	Number Analyzed	368 participants	367 participants
GHS/OoL, Completion of Treatment/ Early Termination Visit		37.2	40.3
GHS/OoL, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
GHS/OoL, Post-Treatment Follow Up 3 Months		38.9	38.6
GHS/OoL, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
GHS/OoL, Post-Treatment Follow Up 6 Months		39.9	42.1
GHS/OoL, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
GHS/OoL, Post-Treatment Follow Up 9 Months		39.3	38.8
GHS/OoL, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
GHS/OoL, Post-Treatment Follow Up 12 Months		42.2	32.8
GHS/OoL, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
GHS/OoL, Post-Treatment Follow Up 18 Months		35.7	37.5
GHS/OoL, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
GHS/OoL, Post-Treatment Follow Up 24 Months		0	16.7

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9770
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.76 to 1.30
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7317
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.05
	Confidence Interval	(2-Sided) 95% 0.80 to 1.37
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.6937
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.06
	Confidence Interval	(2-Sided) 95% 0.80 to 1.39
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3916
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95% 0.66 to 1.18
	Estimation Comments	[Not Specified]

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3363
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.86
	Confidence Interval	(2-Sided) 95% 0.63 to 1.17
	Estimation Comments	[Not Specified]

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.6761
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.08
	Confidence Interval	(2-Sided) 95% 0.75 to 1.55
	Estimation Comments	[Not Specified]

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6997
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.71 to 1.26
	Estimation Comments	[Not Specified]

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3592
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.19
	Confidence Interval	(2-Sided) 95% 0.82 to 1.72
	Estimation Comments	[Not Specified]

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8798
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.97
	Confidence Interval	(2-Sided) 95% 0.62 to 1.51
	Estimation Comments	[Not Specified]

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3857
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.77
	Confidence Interval	(2-Sided) 95% 0.43 to 1.39
	Estimation Comments	[Not Specified]

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6854
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.85
	Confidence Interval	(2-Sided) 95% 0.39 to 1.85
	Estimation Comments	[Not Specified]

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4533
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.54
	Confidence Interval	(2-Sided) 95% 0.11 to 2.70
	Estimation Comments	[Not Specified]

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3173
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	-33.33
	Confidence Interval	(2-Sided) 95% -100.00 to 75.44
	Estimation Comments	[Not Specified]

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3658
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.13
	Confidence Interval	(2-Sided) 95% 0.87 to 1.47
	Estimation Comments	[Not Specified]

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7619
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.04
	Confidence Interval	(2-Sided) 95% 0.80 to 1.36
	Estimation Comments	[Not Specified]

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6580
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.06
	Confidence Interval	(2-Sided) 95% 0.81 to 1.40
	Estimation Comments	[Not Specified]

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2726
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.18
	Confidence Interval	(2-Sided) 95% 0.88 to 1.57
	Estimation Comments	[Not Specified]

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6973
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.69 to 1.29
	Estimation Comments	[Not Specified]

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4470
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.15
	Confidence Interval	(2-Sided) 95% 0.80 to 1.64
	Estimation Comments	[Not Specified]

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5150
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.91
	Confidence Interval	(2-Sided) 95% 0.68 to 1.21
	Estimation Comments	[Not Specified]

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2103
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.26
	Confidence Interval	(2-Sided) 95% 0.88 to 1.82
	Estimation Comments	[Not Specified]

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7969
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.06
	Confidence Interval	(2-Sided) 95% 0.68 to 1.66
	Estimation Comments	[Not Specified]

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8300
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.07
	Confidence Interval	(2-Sided) 95% 0.60 to 1.91
	Estimation Comments	[Not Specified]

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6987
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.17
	Confidence Interval	(2-Sided) 95% 0.53 to 2.55
	Estimation Comments	[Not Specified]

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1441
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	3.32
	Confidence Interval	(2-Sided) 95% 0.62 to 17.77
	Estimation Comments	[Not Specified]

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3173
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in proportion of Responders
	Estimated Value	-66.67
	Confidence Interval	(2-Sided) 95% -100.00 to 4.39
	Estimation Comments	[Not Specified]

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7591
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.96
	Confidence Interval	(2-Sided) 95% 0.74 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5403
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.09
	Confidence Interval	(2-Sided) 95% 0.83 to 1.42
	Estimation Comments	[Not Specified]

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2654
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.17
	Confidence Interval	(2-Sided) 95% 0.89 to 1.55
	Estimation Comments	[Not Specified]

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.5138
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.10
	Confidence Interval	(2-Sided) 95% 0.82 to 1.48
	Estimation Comments	[Not Specified]

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2138
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.22
	Confidence Interval	(2-Sided) 95% 0.89 to 1.67
	Estimation Comments	[Not Specified]

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2114
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.26
	Confidence Interval	(2-Sided) 95% 0.88 to 1.82
	Estimation Comments	[Not Specified]

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3938
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.14
	Confidence Interval	(2-Sided) 95% 0.85 to 1.53
	Estimation Comments	[Not Specified]

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7793
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.95
	Confidence Interval	(2-Sided) 95% 0.65 to 1.38
	Estimation Comments	[Not Specified]

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7370
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.08
	Confidence Interval	(2-Sided) 95% 0.69 to 1.39
	Estimation Comments	[Not Specified]

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9658
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95% 0.55 to 1.79
	Estimation Comments	[Not Specified]

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3015
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.66
	Confidence Interval	(2-Sided) 95% 0.29 to 1.46
	Estimation Comments	[Not Specified]

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7534
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.77
	Confidence Interval	(2-Sided) 95% 0.15 to 3.94
	Estimation Comments	[Not Specified]

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/ QoL, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5637
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	16.67
	Confidence Interval	(2-Sided) 95% -46.49 to 79.82
	Estimation Comments	[Not Specified]

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1177
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.80
	Confidence Interval	(2-Sided) 95% 0.61 to 1.06
	Estimation Comments	[Not Specified]

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2730
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.17
	Confidence Interval	(2-Sided) 95% 0.88 to 1.56
	Estimation Comments	[Not Specified]

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9306
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95% 0.73 to 1.33
	Estimation Comments	[Not Specified]

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8631
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.97
	Confidence Interval	(2-Sided) 95% 0.72 to 1.32
	Estimation Comments	[Not Specified]

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0977
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.33
	Confidence Interval	(2-Sided) 95% 0.95 to 1.86
	Estimation Comments	[Not Specified]

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0726
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.43
	Confidence Interval	(2-Sided) 95% 0.97 to 2.10
	Estimation Comments	[Not Specified]

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9974
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.73 to 1.38
	Estimation Comments	[Not Specified]

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7069
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.08
	Confidence Interval	(2-Sided) 95% 0.72 to 1.63
	Estimation Comments	[Not Specified]

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3068
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.30
	Confidence Interval	(2-Sided) 95% 0.78 to 2.16
	Estimation Comments	[Not Specified]

Statistical Analysis 49

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1375
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.64
	Confidence Interval	(2-Sided) 95% 0.85 to 3.16
	Estimation Comments	[Not Specified]

Statistical Analysis 50

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9540
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.02
	Confidence Interval	(2-Sided) 95% 0.46 to 2.29
	Estimation Comments	[Not Specified]

Statistical Analysis 51

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4283
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.53
	Confidence Interval	(2-Sided) 95% 0.10 to 2.64
	Estimation Comments	[Not Specified]

Statistical Analysis 52

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	16.67
	Confidence Interval	(2-Sided) 95% -95.56 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 53

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2153
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95% 0.64 to 1.10
	Estimation Comments	[Not Specified]

Statistical Analysis 54

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7878
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.96
	Confidence Interval	(2-Sided) 95% 0.73 to 1.27
	Estimation Comments	[Not Specified]

Statistical Analysis 55

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1544
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.81
	Confidence Interval	(2-Sided) 95% 0.61 to 1.08
	Estimation Comments	[Not Specified]

Statistical Analysis 56

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8017
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.04
	Confidence Interval	(2-Sided) 95% 0.77 to 1.40
	Estimation Comments	[Not Specified]

Statistical Analysis 57

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4295
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95% 0.63 to 1.21
	Estimation Comments	[Not Specified]

Statistical Analysis 58

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9540
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio, log
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95% 0.68 to 1.44
	Estimation Comments	[Not Specified]

Statistical Analysis 59

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7494
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.95
	Confidence Interval	(2-Sided) 95% 0.69 to 1.30
	Estimation Comments	[Not Specified]

Statistical Analysis 60

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6412
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.10
	Confidence Interval	(2-Sided) 95% 0.74 to 1.62
	Estimation Comments	[Not Specified]

Statistical Analysis 61

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8652
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.04
	Confidence Interval	(2-Sided) 95% 0.65 to 1.67
	Estimation Comments	[Not Specified]

Statistical Analysis 62

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6912
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.14
	Confidence Interval	(2-Sided) 95% 0.60 to 2.18
	Estimation Comments	[Not Specified]

Statistical Analysis 63

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5834
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.79
	Confidence Interval	(2-Sided) 95% 0.33 to 1.86
	Estimation Comments	[Not Specified]

Statistical Analysis 64

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9578
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.93
	Confidence Interval	(2-Sided) 95% 0.05 to 16.05
	Estimation Comments	[Not Specified]

Statistical Analysis 65

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social Functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5637
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	16.67
	Confidence Interval	(2-Sided) 95% -46.49 to 79.82
	Estimation Comments	[Not Specified]

13.Secondary Outcome


Title	Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group
Description	Percentage of participants with deterioration in patient-reported func...
Description	Percentage of participants with deterioration in patient-reported function and HRQoL, defined as >= 10 points decrease from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Time Frame	From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 60 months). Cycle length=21 days.

Outcome Measure Data

Analysis Population Description

PRO-evaluable population is defined as patients in the ITT population with a baseline and >=1 post-baseline PRO assessment.


Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		473	473
Measure Type: Number Unit of Measure: Percentage of participants
Physical Functioning, Cycle 3 Day 1	Number Analyzed	456 participants	444 participants
Physical Functioning, Cycle 3 Day 1		24.1	24.1
Physical Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	423 participants
Physical Functioning, Cycle 5 Day 1		27.1	28.6
Physical Functioning, Cycle 8 Day 1	Number Analyzed	414 participants	403 participants
Physical Functioning, Cycle 8 Day 1		23.4	23.6
Physical Functioning, Cycle 12 Day 1	Number Analyzed	378 participants	358 participants
Physical Functioning, Cycle 12 Day 1		17.2	16.5
Physical Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Physical Functioning, Cycle 16 Day 1		17.1	17.0
Physical Functioning, Cycle 20 Day 1	Number Analyzed	253 participants	234 participants
Physical Functioning, Cycle 20 Day 1		18.2	16.7
Physical Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	370 participants	366 participants
		20.5	25.1
Physical Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	235 participants	236 participants
Physical Functioning, Post-Treatment Follow Up 3 Months		22.6	23.7
Physical Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	147 participants	164 participants
Physical Functioning, Post-Treatment Follow Up 6 Months		24.5	25.0
Physical Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Physical Functioning, Post-Treatment Follow Up 9 Months		19.0	25.5
Physical Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Physical Functioning, Post-Treatment Follow Up 12 Months		17.8	25.9
Physical Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Physical Functioning, Post-Treatment Follow Up 18 Months		21.4	25.0
Physical Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Physical Functioning, Post-Treatment Follow Up 24 Months		0	50
Role Functioning, Cycle 3 Day 1	Number Analyzed	455 participants	443 participants
Role Functioning, Cycle 3 Day 1		21.3	27.8
Role Functioning, Cycle 5 Day 1	Number Analyzed	438 participants	422 participants
Role Functioning, Cycle 5 Day 1		26.7	27.0
Role Functioning, Cycle 8 Day 1	Number Analyzed	413 participants	401 participants
Role Functioning, Cycle 8 Day 1		21.1	22.7
Role Functioning, Cycle 12 Day 1	Number Analyzed	377 participants	358 participants
Role Functioning, Cycle 12 Day 1		16.7	16.8
Role Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	311 participants
Role Functioning, Cycle 16 Day 1		20.1	15.8
Role Functioning, Cycle 20 Day 1	Number Analyzed	253 participants	233 participants
Role Functioning, Cycle 20 Day 1		18.6	13.3
Role Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	370 participants	367 participants
		23.0	24.3
Role Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	235 participants	236 participants
Role Functioning, Post-Treatment Follow Up 3 Months		20.9	27.1
Role Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	147 participants	164 participants
Role Functioning, Post-Treatment Follow Up 6 Months		20.4	25.6
Role Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Role Functioning, Post-Treatment Follow Up 9 Months		19.0	26.5
Role Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Role Functioning, Post-Treatment Follow Up 12 Months		6.7	37.9
Role Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Role Functioning, Post-Treatment Follow Up 18 Months		7.1	31.3
Role Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Role Functioning, Post-Treatment Follow Up 24 Months		0	16.7
Social Functioning, Cycle 3 Day 1	Number Analyzed	455 participants	442 participants
Social Functioning, Cycle 3 Day 1		29.0	31.2
Social Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
Social Functioning, Cycle 5 Day 1		29.6	30.6
Social Functioning, Cycle 8 Day 1	Number Analyzed	413 participants	403 participants
Social Functioning, Cycle 8 Day 1		21.8	25.8
Social Functioning, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
Social Functioning, Cycle 12 Day 1		18.9	19.0
Social Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Social Functioning, Cycle 16 Day 1		19.5	17.6
Social Functioning, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
Social Functioning, Cycle 20 Day 1		20.2	16.2
Social Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	367 participants	367 participants
		27.2	28.1
Social Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
Social Functioning, Post-Treatment Follow Up 3 Months		26.5	25.4
Social Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
Social Functioning, Post-Treatment Follow Up 6 Months		23.0	30.5
Social Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Social Functioning, Post-Treatment Follow Up 9 Months		22.6	32.7
Social Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Social Functioning, Post-Treatment Follow Up 12 Months		8.9	37.9
Social Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Social Functioning, Post-Treatment Follow Up 18 Months		14.3	37.5
Social Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Social Functioning, Post-Treatment Follow Up 24 Months		0	33.3
Emotional Functioning, Cycle 3 Day 1	Number Analyzed	454 participants	443 participants
Emotional Functioning, Cycle 3 Day 1		12.8	14.0
Emotional Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
Emotional Functioning, Cycle 5 Day 1		17.3	15.9
Emotional Functioning, Cycle 8 Day 1	Number Analyzed	412 participants	403 participants
Emotional Functioning, Cycle 8 Day 1		14.6	12.4
Emotional Functioning, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
Emotional Functioning, Cycle 12 Day 1		12.2	13.4
Emotional Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Emotional Functioning, Cycle 16 Day 1		13.2	12.5
Emotional Functioning, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
Emotional Functioning, Cycle 20 Day 1		15.5	11.1
Emotional Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	368 participants	367 participants
		19.3	19.3
Emotional Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
Emotional Functioning, Post-Treatment Follow Up 3 Months		19.7	16.9
Emotional Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
Emotional Functioning, Post-Treatment Follow Up 6 Months		20.9	14.6
Emotional Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Emotional Functioning, Post-Treatment Follow Up 9 Months		8.3	18.4
Emotional Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Emotional Functioning, Post-Treatment Follow Up 12 Months		8.9	22.4
Emotional Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Emotional Functioning, Post-Treatment Follow Up 18 Months		7.1	31.3
Emotional Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Emotional Functioning, Post-Treatment Follow Up 24 Months		0	66.7
GHS/OoL Function, Cycle 3 Day 1	Number Analyzed	455 participants	443 participants
GHS/OoL Function, Cycle 3 Day 1		24.2	22.8
GHS/OoL Function, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
GHS/OoL Function, Cycle 5 Day 1		24.1	23.7
GHS/OoL Function, Cycle 8 Day 1	Number Analyzed	413 participants	403 participants
GHS/OoL Function, Cycle 8 Day 1		21.3	18.1
GHS/OoL Function, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
GHS/OoL Function, Cycle 12 Day 1		17.6	13.2
GHS/OoL Function, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
GHS/OoL Function, Cycle 16 Day 1		18.3	13.5
GHS/OoL Function, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
GHS/OoL Function, Cycle 20 Day 1		20.2	11.1
GHS/OoL Function, Completion of Treatment/ Early Termination Visit	Number Analyzed	368 participants	367 participants
		24.5	24.3
GHS/OoL Function, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
GHS/OoL Function, Post-Treatment Follow Up 3 Months		20.5	22.9
GHS/OoL Function, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
GHS/OoL Function, Post-Treatment Follow Up 6 Months		20.9	23.8
GHS/OoL Function, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
GHS/OoL Function, Post-Treatment Follow Up 9 Months		21.4	25.5
GHS/OoL Function, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
GHS/OoL Function, Post-Treatment Follow Up 12 Months		17.8	34.5
GHS/OoL Function, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
GHS/OoL Function, Post-Treatment Follow Up 18 Months		21.4	43.8
GHS/OoL Function, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
GHS/OoL Function, Post-Treatment Follow Up 24 Months		0	50

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6063
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.11
	Confidence Interval	(2-Sided) 95% 0.75 to 1.63
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5739
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.90
	Confidence Interval	(2-Sided) 95% 0.63 to 1.29
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3792
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95% 0.56 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6022
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.12
	Confidence Interval	(2-Sided) 95% 0.73 to 1.73
	Estimation Comments	[Not Specified]

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7893
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.59 to 1.49
	Estimation Comments	[Not Specified]

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.2125
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.71
	Confidence Interval	(2-Sided) 95% 0.42 to 1.22
	Estimation Comments	[Not Specified]

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9661
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.01
	Confidence Interval	(2-Sided) 95% 0.70 to 1.46
	Estimation Comments	[Not Specified]

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4299
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.83
	Confidence Interval	(2-Sided) 95% 0.52 to 1.32
	Estimation Comments	[Not Specified]

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1542
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.65
	Confidence Interval	(2-Sided) 95% 0.36 to 1.18
	Estimation Comments	[Not Specified]

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0363
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.65
	Confidence Interval	(2-Sided) 95% 1.04 to 6.76
	Estimation Comments	[Not Specified]

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0814
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.75
	Confidence Interval	(2-Sided) 95% 0.85 to 8.93
	Estimation Comments	[Not Specified]

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1915
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	4.03
	Confidence Interval	(2-Sided) 95% 0.43 to 38.00
	Estimation Comments	[Not Specified]

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3173
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	66.67
	Confidence Interval	(2-Sided) 95% -4.39 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9818
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.73 to 1.35
	Estimation Comments	[Not Specified]

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6263
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.08
	Confidence Interval	(2-Sided) 95% 0.80 to 1.45
	Estimation Comments	[Not Specified]

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9407
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.01
	Confidence Interval	(2-Sided) 95% 0.73 to 1.40
	Estimation Comments	[Not Specified]

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7700
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.64 to 1.39
	Estimation Comments	[Not Specified]

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8458
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.96
	Confidence Interval	(2-Sided) 95% 0.63 to 1.45
	Estimation Comments	[Not Specified]

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7028
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.91
	Confidence Interval	(2-Sided) 95% 0.57 to 1.46
	Estimation Comments	[Not Specified]

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.1391
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.30
	Confidence Interval	(2-Sided) 95% 0.92 to 1.83
	Estimation Comments	[Not Specified]

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8002
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.06
	Confidence Interval	(2-Sided) 95% 0.69 to 1.62
	Estimation Comments	[Not Specified]

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9751
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.01
	Confidence Interval	(2-Sided) 95% 0.60 to 1.68
	Estimation Comments	[Not Specified]

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3811
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.37
	Confidence Interval	(2-Sided) 95% 0.68 to 2.78
	Estimation Comments	[Not Specified]

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3950
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.51
	Confidence Interval	(2-Sided) 95% 0.58 to 3.90
	Estimation Comments	[Not Specified]

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8993
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.89
	Confidence Interval	(2-Sided) 95% 0.16 to 5.12
	Estimation Comments	[Not Specified]

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified

Statistical Test of Hypothesis	P-Value	0.3173
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -23.34 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5988
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.68 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8859
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.98
	Confidence Interval	(2-Sided) 95% 0.72 to 1.34
	Estimation Comments	[Not Specified]

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2531
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.82
	Confidence Interval	(2-Sided) 95% 0.58 to 1.16
	Estimation Comments	[Not Specified]

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0785
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.69
	Confidence Interval	(2-Sided) 95% 0.46 to 1.04
	Estimation Comments	[Not Specified]

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0641
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.67
	Confidence Interval	(2-Sided) 95% 0.43 to 1.03
	Estimation Comments	[Not Specified]

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0046
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.48
	Confidence Interval	(2-Sided) 95% 0.29 to 0.80
	Estimation Comments	[Not Specified]

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8928
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.98
	Confidence Interval	(2-Sided) 95% 0.70 to 1.37
	Estimation Comments	[Not Specified]

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6106
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.12
	Confidence Interval	(2-Sided) 95% 0.72 to 1.74
	Estimation Comments	[Not Specified]

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6159
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.15
	Confidence Interval	(2-Sided) 95% 0.67 to 1.95
	Estimation Comments	[Not Specified]

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5372
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.24
	Confidence Interval	(2-Sided) 95% 0.62 to 2.49
	Estimation Comments	[Not Specified]

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0845
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.22
	Confidence Interval	(2-Sided) 95% 0.89 to 5.58
	Estimation Comments	[Not Specified]

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1344
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	3.67
	Confidence Interval	(2-Sided) 95% 0.62 to 21.56
	Estimation Comments	[Not Specified]

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3173
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -23.34 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0260
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.41
	Confidence Interval	(2-Sided) 95% 1.04 to 1.92
	Estimation Comments	[Not Specified]

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9179
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.02
	Confidence Interval	(2-Sided) 95% 0.75 to 1.37
	Estimation Comments	[Not Specified]

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5820
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.10
	Confidence Interval	(2-Sided) 95% 0.79 to 1.53
	Estimation Comments	[Not Specified]

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9772
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95% 0.67 to 1.47
	Estimation Comments	[Not Specified]

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1300
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.73
	Confidence Interval	(2-Sided) 95% 0.49 to 1.10
	Estimation Comments	[Not Specified]

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0990
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.66
	Confidence Interval	(2-Sided) 95% 0.40 to 1.08
	Estimation Comments	[Not Specified]

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7133
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.07
	Confidence Interval	(2-Sided) 95% 0.76 to 1.50
	Estimation Comments	[Not Specified]

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1384
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.38
	Confidence Interval	(2-Sided) 95% 0.90 to 2.11
	Estimation Comments	[Not Specified]

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2895
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.33
	Confidence Interval	(2-Sided) 95% 0.78 to 2.26
	Estimation Comments	[Not Specified]

Statistical Analysis 49

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2221
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.55
	Confidence Interval	(2-Sided) 95% 0.77 to 3.14
	Estimation Comments	[Not Specified]

Statistical Analysis 50

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0005
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	7.37
	Confidence Interval	(2-Sided) 95% 2.08 to 26.10
	Estimation Comments	[Not Specified]

Statistical Analysis 51

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.2171
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	3.72
	Confidence Interval	(2-Sided) 95% 0.40 to 34.56
	Estimation Comments	[Not Specified]

Statistical Analysis 52

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	16.67
	Confidence Interval	(2-Sided) 95% -46.49 to 79.82
	Estimation Comments	[Not Specified]

Statistical Analysis 53

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4647
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.11
	Confidence Interval	(2-Sided) 95% 0.84 to 1.48
	Estimation Comments	[Not Specified]

Statistical Analysis 54

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7676
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.04
	Confidence Interval	(2-Sided) 95% 0.78 to 1.40
	Estimation Comments	[Not Specified]

Statistical Analysis 55

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1983
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.24
	Confidence Interval	(2-Sided) 95% 0.89 to 1.71
	Estimation Comments	[Not Specified]

Statistical Analysis 56

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9874
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.69 to 1.44
	Estimation Comments	[Not Specified]

Statistical Analysis 57

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4716
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.86
	Confidence Interval	(2-Sided) 95% 0.58 to 1.29
	Estimation Comments	[Not Specified]

Statistical Analysis 58

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2041
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.74
	Confidence Interval	(2-Sided) 95% 0.46 to 1.18
	Estimation Comments	[Not Specified]

Statistical Analysis 59

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7771
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.05
	Confidence Interval	(2-Sided) 95% 0.76 to 1.45
	Estimation Comments	[Not Specified]

Statistical Analysis 60

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8542
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.96
	Confidence Interval	(2-Sided) 95% 0.64 to 1.45
	Estimation Comments	[Not Specified]

Statistical Analysis 61

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1230
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.50
	Confidence Interval	(2-Sided) 95% 0.90 to 2.50
	Estimation Comments	[Not Specified]

Statistical Analysis 62

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1089
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.72
	Confidence Interval	(2-Sided) 95% 0.88 to 3.34
	Estimation Comments	[Not Specified]

Statistical Analysis 63

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0011
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	5.82
	Confidence Interval	(2-Sided) 95% 1.85 to 18.30
	Estimation Comments	[Not Specified]

Statistical Analysis 64

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2950
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.51
	Confidence Interval	(2-Sided) 95% 0.43 to 14.74
	Estimation Comments	[Not Specified]

Statistical Analysis 65

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	33.33
	Confidence Interval	(2-Sided) 95% -37.72 to 100.00
	Estimation Comments	[Not Specified]

14.Secondary Outcome


Title	Percentage of Participants With at Least One Adverse Event
Description	Percentage of participants with at least one adverse event.
Description	Percentage of participants with at least one adverse event.
Time Frame	From randomization up to approximately 59 months

Outcome Measure Data

Analysis Population Description

Safety-evaluable population is defined as patients who received any amount of any study treatment (atezolizumab, placebo, paclitaxel, carboplatin, or bevacizumab).


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	644	642
Measure Type: Number Unit of Measure: Percentage
	99.8	100

15.Secondary Outcome


Title	Maximum Serum Concentration (Cmax) of Atezolizumab
Description	[Not Specified]
Description	[Not Specified]
Time Frame	Cycle 1 Day 1 post dose and Cycle 3 Day 1 post dose

Outcome Measure Data

Analysis Population Description

PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.


Arm/Group Title		Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		538
Mean (Standard Deviation) Unit of Measure: µg/mL
Cycle 1 Day 1	Number Analyzed	538 participants
Cycle 1 Day 1		487 (163)
Cycle 3 Day 1	Number Analyzed	499 participants
Cycle 3 Day 1		614 (209)

16.Secondary Outcome


Title	Minimum Serum Concentration (Cmin) of Atezolizumab
Description	[Not Specified]
Description	[Not Specified]
Time Frame	Cycle 2 Day 1 predose, Cycle 3 Day 1 Predose, Cycle 4 Day 1 predose, Cycle 8 Day 1 predose, Cycle 16 Day 1 predose

Outcome Measure Data

Analysis Population Description

PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.


Arm/Group Title		Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		532
Mean (Standard Deviation) Unit of Measure: µg/mL
Cycle 2 Day 1	Number Analyzed	532 participants
Cycle 2 Day 1		88.9 (35.8)
Cycle 3 Day 1	Number Analyzed	519 participants
Cycle 3 Day 1		146 (93.0)
Cycle 4 Day 1	Number Analyzed	502 participants
Cycle 4 Day 1		149 (88.1)
Cycle 8 Day 1	Number Analyzed	339 participants
Cycle 8 Day 1		242 (96.3)
Cycle 16 Day 1	Number Analyzed	213 participants
Cycle 16 Day 1		286 (111)

17.Secondary Outcome


Title	Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Description	[Not Specified]
Description	[Not Specified]
Time Frame	Baseline to approximately 55 months

Outcome Measure Data

Analysis Population Description

PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.


Arm/Group Title		Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		569
Measure Type: Number Unit of Measure: Percentage of participants
Baseline evaluable participants	Number Analyzed	563 participants
Baseline evaluable participants		0.7
Post-baseline evaluable participants	Number Analyzed	569 participants
Post-baseline evaluable participants		22.7

Adverse Events

Time Frame	From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months)
Adverse Event Reporting Description	All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious & other adverse events reported based on safety population, which included participants who received any amount of any study drug.

Arm/Group Title	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab		Placebo With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description	Participants in the primary tumor-r...		Participants in the primary tumor-r...
Arm/Group Description	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.
All-Cause Mortality
	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab		Placebo With Paclitaxel, Carboplatin and Bevacizumab
	Affected / at Risk (%)		Affected / at Risk (%)
Total	272/651 (41.78%)		289/650 (44.46%)
Serious Adverse Events Serious Adverse Events
	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab		Placebo With Paclitaxel, Carboplatin and Bevacizumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	304/642 (47.35%)		215/644 (33.39%)
Blood and lymphatic system disorders
AGRANULOCYTOSIS ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
ANAEMIA ^† 1	6/642 (0.93%)	7	10/644 (1.55%)	10
FEBRILE NEUTROPENIA ^† 1	54/642 (8.41%)	59	24/644 (3.73%)	25
GRANULOCYTOSIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
IMMUNE THROMBOCYTOPENIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
LEUKOPENIA ^† 1	3/642 (0.47%)	3	2/644 (0.31%)	2
NEUTROPENIA ^† 1	5/642 (0.78%)	5	5/644 (0.78%)	5
PANCYTOPENIA ^† 1	1/642 (0.16%)	1	2/644 (0.31%)	2
THROMBOCYTOPENIA ^† 1	8/642 (1.25%)	11	10/644 (1.55%)	12
THROMBOTIC MICROANGIOPATHY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
MYELOSUPPRESSION ^† 1	3/642 (0.47%)	5	2/644 (0.31%)	2
Cardiac disorders
ACUTE MYOCARDIAL INFARCTION ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
ANGINA UNSTABLE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ARRHYTHMIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ATRIAL FIBRILLATION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ATRIAL TACHYCARDIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ATRIAL THROMBOSIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ATRIOVENTRICULAR BLOCK ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
CARDIAC ARREST ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
CARDIAC FAILURE ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
CARDIAC FAILURE CONGESTIVE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
CARDIOMYOPATHY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
CARDIOVASCULAR DISORDER ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
MYOCARDIAL INFARCTION ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
MYOCARDIAL ISCHAEMIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
MYOCARDITIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
PALPITATIONS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Ear and labyrinth disorders
OTOLITHIASIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
VERTIGO ^† 1	0/642 (0.00%)	0	3/644 (0.47%)	3
Endocrine disorders
ADDISON'S DISEASE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ADRENAL INSUFFICIENCY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
AUTOIMMUNE THYROIDITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HYPERPARATHYROIDISM ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HYPOTHYROIDISM ^† 1	2/642 (0.31%)	2	1/644 (0.16%)	1
SECONDARY ADRENOCORTICAL INSUFFICIENCY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Eye disorders
OCULAR MYASTHENIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
OPTIC NEUROPATHY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
RETINAL VEIN OCCLUSION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ULCERATIVE KERATITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Gastrointestinal disorders
ABDOMINAL ADHESIONS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
ABDOMINAL DISTENSION ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
ABDOMINAL HERNIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ABDOMINAL PAIN ^† 1	9/642 (1.40%)	9	2/644 (0.31%)	2
ABDOMINAL PAIN LOWER ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
ABDOMINAL PAIN UPPER ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
ANAL FISTULA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ANAL HAEMORRHAGE ^† 1	1/642 (0.16%)	2	0/644 (0.00%)	0
ASCITES ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
COLITIS ^† 1	11/642 (1.71%)	12	6/644 (0.93%)	6
CONSTIPATION ^† 1	4/642 (0.62%)	4	5/644 (0.78%)	5
DIARRHOEA ^† 1	9/642 (1.40%)	11	11/644 (1.71%)	13
DIARRHOEA HAEMORRHAGIC ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
DIVERTICULAR PERFORATION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DIVERTICULUM ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
DUODENAL PERFORATION ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
DYSPEPSIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DYSPHAGIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ENTERITIS ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
ENTEROCOLITIS ^† 1	1/642 (0.16%)	1	4/644 (0.62%)	4
ENTEROCUTANEOUS FISTULA ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
GASTRIC STENOSIS ^† 1	1/642 (0.16%)	4	0/644 (0.00%)	0
GASTRITIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
GASTROINTESTINAL HAEMORRHAGE ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
GASTROINTESTINAL PERFORATION ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
GINGIVAL PAIN ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HAEMORRHOIDAL HAEMORRHAGE ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
ILEAL PERFORATION ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
ILEUS ^† 1	12/642 (1.87%)	14	8/644 (1.24%)	10
ILEUS PARALYTIC ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
INCARCERATED INGUINAL HERNIA ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
INCARCERATED UMBILICAL HERNIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
INTESTINAL OBSTRUCTION ^† 1	8/642 (1.25%)	8	7/644 (1.09%)	9
INTESTINAL PERFORATION ^† 1	2/642 (0.31%)	2	3/644 (0.47%)	3
LARGE INTESTINAL HAEMORRHAGE ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
LARGE INTESTINAL OBSTRUCTION ^† 1	1/642 (0.16%)	1	2/644 (0.31%)	2
LARGE INTESTINE PERFORATION ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
LOWER GASTROINTESTINAL HAEMORRHAGE ^† 1	2/642 (0.31%)	2	1/644 (0.16%)	1
MECHANICAL ILEUS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
NAUSEA ^† 1	5/642 (0.78%)	5	5/644 (0.78%)	5
OBSTRUCTION GASTRIC ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
OESOPHAGITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ORAL LICHEN PLANUS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
PANCREATIC FISTULA ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
PANCREATITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
PERITONEAL ADHESIONS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
PNEUMATOSIS INTESTINALIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
RECTAL HAEMORRHAGE ^† 1	3/642 (0.47%)	3	1/644 (0.16%)	1
SMALL INTESTINAL OBSTRUCTION ^† 1	10/642 (1.56%)	11	6/644 (0.93%)	6
SMALL INTESTINAL PERFORATION ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
SUBILEUS ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
THROMBOSIS MESENTERIC VESSEL ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
UMBILICAL HERNIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
VOMITING ^† 1	4/642 (0.62%)	5	7/644 (1.09%)	8
General disorders
ASTHENIA ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
CONDITION AGGRAVATED ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
DEATH ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
DEVICE RELATED THROMBOSIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
EARLY SATIETY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
FATIGUE ^† 1	4/642 (0.62%)	4	2/644 (0.31%)	2
GENERAL PHYSICAL HEALTH DETERIORATION ^† 1	3/642 (0.47%)	4	0/644 (0.00%)	0
MUCOSAL INFLAMMATION ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
MULTIPLE ORGAN DYSFUNCTION SYNDROME ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
NON-CARDIAC CHEST PAIN ^† 1	2/642 (0.31%)	2	2/644 (0.31%)	2
PAIN ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
PYREXIA ^† 1	26/642 (4.05%)	31	8/644 (1.24%)	9
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Hepatobiliary disorders
CHOLESTASIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DRUG-INDUCED LIVER INJURY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HEPATIC FUNCTION ABNORMAL ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
HEPATOTOXICITY ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
IMMUNE-MEDIATED HEPATITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
JAUNDICE ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
JAUNDICE CHOLESTATIC ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
LIVER INJURY ^† 1	4/642 (0.62%)	4	1/644 (0.16%)	1
HEPATIC FAILURE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Immune system disorders
ANAPHYLACTIC REACTION ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
ANAPHYLACTIC SHOCK ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
CONTRAST MEDIA ALLERGY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
CYTOKINE RELEASE SYNDROME ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DRUG HYPERSENSITIVITY ^† 1	1/642 (0.16%)	1	3/644 (0.47%)	3
HYPERSENSITIVITY ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
IMMUNE-MEDIATED ADVERSE REACTION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
SYSTEMIC IMMUNE ACTIVATION ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
SARCOIDOSIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
Infections and infestations
ABDOMINAL ABSCESS ^† 1	5/642 (0.78%)	5	3/644 (0.47%)	3
ABDOMINAL INFECTION ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
APPENDICITIS ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
BACTERAEMIA ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	3
BRONCHITIS ^† 1	2/642 (0.31%)	2	2/644 (0.31%)	2
BRONCHITIS VIRAL ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
CELLULITIS ^† 1	3/642 (0.47%)	3	2/644 (0.31%)	2
CLOSTRIDIUM DIFFICILE COLITIS ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
CLOSTRIDIUM DIFFICILE INFECTION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DEVICE RELATED INFECTION ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
ENCEPHALITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
EPSTEIN-BARR VIRUS INFECTION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ESCHERICHIA BACTERAEMIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
FOURNIER'S GANGRENE ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
GASTROENTERITIS CLOSTRIDIAL ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
GINGIVITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HERPES ZOSTER ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
INFECTED LYMPHOCELE ^† 1	4/642 (0.62%)	4	1/644 (0.16%)	1
INFECTION ^† 1	3/642 (0.47%)	3	1/644 (0.16%)	1
INFECTIOUS MONONUCLEOSIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
INFLUENZA ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
KIDNEY INFECTION ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
LYMPHANGITIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
MENINGITIS BACTERIAL ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
MENINGOENCEPHALITIS HERPETIC ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
NASOPHARYNGITIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
PELVIC ABSCESS ^† 1	2/642 (0.31%)	2	1/644 (0.16%)	1
PELVIC INFECTION ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
PERITONITIS ^† 1	4/642 (0.62%)	4	0/644 (0.00%)	0
PERITONSILLITIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
PNEUMONIA ^† 1	10/642 (1.56%)	10	7/644 (1.09%)	7
PNEUMONIA BACTERIAL ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
PNEUMONIA VIRAL ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
POSTOPERATIVE ABSCESS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
POSTOPERATIVE WOUND INFECTION ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
PULPITIS DENTAL ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
PYELONEPHRITIS ^† 1	4/642 (0.62%)	5	3/644 (0.47%)	3
PYELONEPHRITIS ACUTE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
SEPSIS ^† 1	3/642 (0.47%)	3	9/644 (1.40%)	9
SKIN INFECTION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
STAPHYLOCOCCAL SEPSIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
TONSILLITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
UPPER RESPIRATORY TRACT INFECTION ^† 1	4/642 (0.62%)	4	1/644 (0.16%)	1
URINARY TRACT INFECTION ^† 1	9/642 (1.40%)	9	5/644 (0.78%)	6
UROSEPSIS ^† 1	4/642 (0.62%)	4	2/644 (0.31%)	2
VAGINAL ABSCESS ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
VAGINAL CELLULITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
VASCULAR DEVICE INFECTION ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
WOUND INFECTION ^† 1	0/642 (0.00%)	0	3/644 (0.47%)	3
BACTERIAL SEPSIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DIVERTICULITIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
GASTROENTERITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Injury, poisoning and procedural complications
ANKLE FRACTURE ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
CONCUSSION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
FALL ^† 1	2/642 (0.31%)	2	1/644 (0.16%)	1
FASCIAL RUPTURE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
FOOT FRACTURE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
FRACTURE ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
FRACTURED SACRUM ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
GASTROINTESTINAL ANASTOMOTIC LEAK ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
GASTROINTESTINAL INJURY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HIP FRACTURE ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
INCISION SITE IMPAIRED HEALING ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
INCISIONAL HERNIA ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
INFUSION RELATED REACTION ^† 1	5/642 (0.78%)	5	2/644 (0.31%)	2
PERIPROSTHETIC FRACTURE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
POST PROCEDURAL HAEMORRHAGE ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
PROCEDURAL INTESTINAL PERFORATION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
SPINAL COMPRESSION FRACTURE ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
VAGINAL CUFF DEHISCENCE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
WOUND COMPLICATION ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	3
WOUND DEHISCENCE ^† 1	2/642 (0.31%)	2	3/644 (0.47%)	5
STOMA PROLAPSE ^† 1	1/642 (0.16%)	1	2/644 (0.31%)	2
Investigations
ALANINE AMINOTRANSFERASE INCREASED ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ASPARTATE AMINOTRANSFERASE INCREASED ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
BLOOD CREATININE INCREASED ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
BLOOD POTASSIUM DECREASED ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
C-REACTIVE PROTEIN INCREASED ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HEPATIC ENZYME INCREASED ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
INTERNATIONAL NORMALISED RATIO INCREASED ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
LIPASE INCREASED ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
LYMPHOCYTE COUNT DECREASED ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
NEUTROPHIL COUNT DECREASED ^† 1	3/642 (0.47%)	3	7/644 (1.09%)	7
PLATELET COUNT DECREASED ^† 1	6/642 (0.93%)	9	10/644 (1.55%)	13
WHITE BLOOD CELL COUNT DECREASED ^† 1	3/642 (0.47%)	3	2/644 (0.31%)	3
Metabolism and nutrition disorders
DECREASED APPETITE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DEHYDRATION ^† 1	6/642 (0.93%)	6	0/644 (0.00%)	0
ELECTROLYTE IMBALANCE ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
FOOD REFUSAL ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
HYPERCALCAEMIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HYPERGLYCAEMIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HYPERMAGNESAEMIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HYPOKALAEMIA ^† 1	1/642 (0.16%)	1	3/644 (0.47%)	3
HYPOMAGNESAEMIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HYPONATRAEMIA ^† 1	4/642 (0.62%)	4	4/644 (0.62%)	5
TYPE 1 DIABETES MELLITUS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Musculoskeletal and connective tissue disorders
ARTHRALGIA ^† 1	1/642 (0.16%)	1	2/644 (0.31%)	2
BACK PAIN ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
FLANK PAIN ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
MYALGIA ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
MYOPATHY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
MYOSITIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
PAIN IN EXTREMITY ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
SPINAL PAIN ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ANAPLASTIC ASTROCYTOMA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
GASTROINTESTINAL STROMAL TUMOUR ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
INVASIVE DUCTAL BREAST CARCINOMA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
PAPILLARY THYROID CANCER ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
Nervous system disorders
APHASIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ATAXIA ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
CEREBELLAR INFARCTION ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
CEREBRAL INFARCTION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
CEREBROVASCULAR ACCIDENT ^† 1	2/642 (0.31%)	3	3/644 (0.47%)	3
COGNITIVE DISORDER ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DEMENTIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DEPRESSED LEVEL OF CONSCIOUSNESS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
DIZZINESS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
ENCEPHALOPATHY ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
EPILEPSY ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
HAEMORRHAGE INTRACRANIAL ^† 1	2/642 (0.31%)	2	1/644 (0.16%)	1
HEADACHE ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
ISCHAEMIC STROKE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
MYASTHENIA GRAVIS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
NEUROPATHY PERIPHERAL ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
PERIPHERAL MOTOR NEUROPATHY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
PRESYNCOPE ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
SEIZURE ^† 1	2/642 (0.31%)	3	0/644 (0.00%)	0
SUBARACHNOID HAEMORRHAGE ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
SYNCOPE ^† 1	2/642 (0.31%)	2	2/644 (0.31%)	2
TRANSIENT ISCHAEMIC ATTACK ^† 1	4/642 (0.62%)	5	2/644 (0.31%)	2
Psychiatric disorders
DELIRIUM ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
DEPRESSION ^† 1	1/642 (0.16%)	1	2/644 (0.31%)	3
SUICIDAL IDEATION ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
Renal and urinary disorders
ACUTE KIDNEY INJURY ^† 1	3/642 (0.47%)	3	2/644 (0.31%)	2
HAEMATURIA ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
HYDRONEPHROSIS ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
IMMUNE-MEDIATED NEPHRITIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
NEPHRITIS ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
NEPHROPATHY ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
PROTEINURIA ^† 1	3/642 (0.47%)	3	3/644 (0.47%)	3
RENAL FAILURE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
URINARY TRACT OBSTRUCTION ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
UROGENITAL FISTULA ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
GLOMERULONEPHRITIS CHRONIC ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
Reproductive system and breast disorders
FEMALE GENITAL TRACT FISTULA ^† 1	2/642 (0.31%)	2	2/644 (0.31%)	2
VAGINAL FISTULA ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
HEAVY MENSTRUAL BLEEDING ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY DISTRESS SYNDROME ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
ASPIRATION ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
CHRONIC OBSTRUCTIVE PULMONARY DISEASE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DYSPNOEA ^† 1	3/642 (0.47%)	3	2/644 (0.31%)	2
EPISTAXIS ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
HYPERVENTILATION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HYPOXIA ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
LOWER RESPIRATORY TRACT CONGESTION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
PLEURAL EFFUSION ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
PNEUMONITIS ^† 1	5/642 (0.78%)	6	2/644 (0.31%)	2
PULMONARY EMBOLISM ^† 1	10/642 (1.56%)	10	6/644 (0.93%)	6
PULMONARY HAEMORRHAGE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Skin and subcutaneous tissue disorders
DRUG ERUPTION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ECZEMA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
ERYTHEMA MULTIFORME ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
LICHEN PLANUS ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
RASH ^† 1	7/642 (1.09%)	7	0/644 (0.00%)	0
RASH MACULO-PAPULAR ^† 1	3/642 (0.47%)	3	0/644 (0.00%)	0
SKIN ULCER ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
STEVENS-JOHNSON SYNDROME ^† 1	2/642 (0.31%)	2	0/644 (0.00%)	0
TOXIC SKIN ERUPTION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
URTICARIA ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
Vascular disorders
AORTIC DISSECTION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
CIRCULATORY COLLAPSE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
DEEP VEIN THROMBOSIS ^† 1	2/642 (0.31%)	2	2/644 (0.31%)	2
EMBOLISM ^† 1	3/642 (0.47%)	3	3/644 (0.47%)	3
EMBOLISM VENOUS ^† 1	0/642 (0.00%)	0	2/644 (0.31%)	2
HAEMORRHAGE ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HYPERTENSION ^† 1	5/642 (0.78%)	5	4/644 (0.62%)	4
HYPERTENSIVE URGENCY ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
HYPOTENSION ^† 1	1/642 (0.16%)	1	1/644 (0.16%)	1
LYMPHOCELE ^† 1	1/642 (0.16%)	1	2/644 (0.31%)	2
LYMPHORRHOEA ^† 1	0/642 (0.00%)	0	1/644 (0.16%)	1
ORTHOSTATIC HYPOTENSION ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
SHOCK HAEMORRHAGIC ^† 1	1/642 (0.16%)	1	0/644 (0.00%)	0
1 Term from vocabulary, MedDRA version 25.0 † Indicates events were collected by systematic assessment
Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events	5%
	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab		Placebo With Paclitaxel, Carboplatin and Bevacizumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	637/642 (99.22%)		637/644 (98.91%)
Blood and lymphatic system disorders
ANAEMIA ^† 1	284/642 (44.24%)	468	266/644 (41.30%)	440
LEUKOPENIA ^† 1	69/642 (10.75%)	197	76/644 (11.80%)	243
NEUTROPENIA ^† 1	195/642 (30.37%)	477	197/644 (30.59%)	507
THROMBOCYTOPENIA ^† 1	137/642 (21.34%)	278	134/644 (20.81%)	275
Endocrine disorders
HYPERTHYROIDISM ^† 1	51/642 (7.94%)	56	23/644 (3.57%)	26
HYPOTHYROIDISM ^† 1	118/642 (18.38%)	131	54/644 (8.39%)	57
Eye disorders
VISION BLURRED ^† 1	31/642 (4.83%)	34	45/644 (6.99%)	48
Gastrointestinal disorders
ABDOMINAL DISTENSION ^† 1	39/642 (6.07%)	51	49/644 (7.61%)	60
ABDOMINAL PAIN ^† 1	182/642 (28.35%)	253	173/644 (26.86%)	241
ABDOMINAL PAIN UPPER ^† 1	49/642 (7.63%)	56	66/644 (10.25%)	98
CONSTIPATION ^† 1	226/642 (35.20%)	297	240/644 (37.27%)	334
DIARRHOEA ^† 1	223/642 (34.74%)	336	199/644 (30.90%)	328
DRY MOUTH ^† 1	34/642 (5.30%)	39	18/644 (2.80%)	22
DYSPEPSIA ^† 1	44/642 (6.85%)	54	53/644 (8.23%)	61
NAUSEA ^† 1	325/642 (50.62%)	565	337/644 (52.33%)	628
STOMATITIS ^† 1	98/642 (15.26%)	138	67/644 (10.40%)	106
VOMITING ^† 1	150/642 (23.36%)	209	156/644 (24.22%)	230
GASTROOESOPHAGEAL REFLUX DISEASE ^† 1	28/642 (4.36%)	29	33/644 (5.12%)	39
General disorders
ASTHENIA ^† 1	78/642 (12.15%)	102	79/644 (12.27%)	117
FATIGUE ^† 1	241/642 (37.54%)	297	251/644 (38.98%)	339
MALAISE ^† 1	35/642 (5.45%)	59	33/644 (5.12%)	42
MUCOSAL INFLAMMATION ^† 1	45/642 (7.01%)	49	26/644 (4.04%)	36
OEDEMA PERIPHERAL ^† 1	40/642 (6.23%)	44	40/644 (6.21%)	42
PYREXIA ^† 1	104/642 (16.20%)	124	54/644 (8.39%)	75
PAIN ^† 1	33/642 (5.14%)	35	32/644 (4.97%)	39
Infections and infestations
NASOPHARYNGITIS ^† 1	41/642 (6.39%)	60	41/644 (6.37%)	59
UPPER RESPIRATORY TRACT INFECTION ^† 1	63/642 (9.81%)	83	55/644 (8.54%)	71
URINARY TRACT INFECTION ^† 1	109/642 (16.98%)	169	104/644 (16.15%)	140
Injury, poisoning and procedural complications
INFUSION RELATED REACTION ^† 1	78/642 (12.15%)	116	50/644 (7.76%)	71
Investigations
ALANINE AMINOTRANSFERASE INCREASED ^† 1	91/642 (14.17%)	142	59/644 (9.16%)	100
ASPARTATE AMINOTRANSFERASE INCREASED ^† 1	89/642 (13.86%)	149	56/644 (8.70%)	93
BLOOD ALKALINE PHOSPHATASE INCREASED ^† 1	40/642 (6.23%)	50	33/644 (5.12%)	48
LYMPHOCYTE COUNT DECREASED ^† 1	42/642 (6.54%)	55	24/644 (3.73%)	44
NEUTROPHIL COUNT DECREASED ^† 1	177/642 (27.57%)	567	168/644 (26.09%)	610
PLATELET COUNT DECREASED ^† 1	137/642 (21.34%)	267	142/644 (22.05%)	329
WEIGHT DECREASED ^† 1	84/642 (13.08%)	91	68/644 (10.56%)	72
WEIGHT INCREASED ^† 1	50/642 (7.79%)	51	44/644 (6.83%)	46
WHITE BLOOD CELL COUNT DECREASED ^† 1	143/642 (22.27%)	455	122/644 (18.94%)	535
Metabolism and nutrition disorders
DECREASED APPETITE ^† 1	119/642 (18.54%)	160	120/644 (18.63%)	154
HYPERGLYCAEMIA ^† 1	46/642 (7.17%)	69	52/644 (8.07%)	85
HYPOKALAEMIA ^† 1	72/642 (11.21%)	97	60/644 (9.32%)	94
HYPOMAGNESAEMIA ^† 1	92/642 (14.33%)	134	83/644 (12.89%)	112
HYPONATRAEMIA ^† 1	48/642 (7.48%)	63	45/644 (6.99%)	61
Musculoskeletal and connective tissue disorders
ARTHRALGIA ^† 1	286/642 (44.55%)	444	285/644 (44.25%)	451
BACK PAIN ^† 1	88/642 (13.71%)	97	90/644 (13.98%)	115
BONE PAIN ^† 1	45/642 (7.01%)	70	51/644 (7.92%)	92
MUSCULAR WEAKNESS ^† 1	45/642 (7.01%)	50	44/644 (6.83%)	57
MYALGIA ^† 1	144/642 (22.43%)	205	163/644 (25.31%)	239
NECK PAIN ^† 1	34/642 (5.30%)	34	32/644 (4.97%)	35
PAIN IN EXTREMITY ^† 1	81/642 (12.62%)	110	89/644 (13.82%)	121
Nervous system disorders
DIZZINESS ^† 1	76/642 (11.84%)	93	80/644 (12.42%)	102
DYSGEUSIA ^† 1	56/642 (8.72%)	66	50/644 (7.76%)	52
HEADACHE ^† 1	149/642 (23.21%)	220	179/644 (27.80%)	278
HYPOAESTHESIA ^† 1	50/642 (7.79%)	63	59/644 (9.16%)	78
NEUROPATHY PERIPHERAL ^† 1	152/642 (23.68%)	175	166/644 (25.78%)	196
PARAESTHESIA ^† 1	47/642 (7.32%)	57	40/644 (6.21%)	65
PERIPHERAL SENSORY NEUROPATHY ^† 1	178/642 (27.73%)	201	163/644 (25.31%)	186
Psychiatric disorders
ANXIETY ^† 1	38/642 (5.92%)	43	49/644 (7.61%)	58
DEPRESSION ^† 1	35/642 (5.45%)	41	38/644 (5.90%)	41
INSOMNIA ^† 1	89/642 (13.86%)	100	97/644 (15.06%)	119
Renal and urinary disorders
PROTEINURIA ^† 1	137/642 (21.34%)	172	140/644 (21.74%)	178
Respiratory, thoracic and mediastinal disorders
COUGH ^† 1	102/642 (15.89%)	127	80/644 (12.42%)	101
DYSPHONIA ^† 1	44/642 (6.85%)	47	44/644 (6.83%)	50
DYSPNOEA ^† 1	87/642 (13.55%)	112	86/644 (13.35%)	110
EPISTAXIS ^† 1	136/642 (21.18%)	166	139/644 (21.58%)	178
NASAL CONGESTION ^† 1	32/642 (4.98%)	38	36/644 (5.59%)	40
OROPHARYNGEAL PAIN ^† 1	47/642 (7.32%)	58	41/644 (6.37%)	50
Skin and subcutaneous tissue disorders
ALOPECIA ^† 1	386/642 (60.12%)	393	410/644 (63.66%)	415
DRY SKIN ^† 1	35/642 (5.45%)	37	33/644 (5.12%)	39
PRURITUS ^† 1	87/642 (13.55%)	108	61/644 (9.47%)	74
RASH ^† 1	152/642 (23.68%)	205	99/644 (15.37%)	119
RASH MACULO-PAPULAR ^† 1	45/642 (7.01%)	67	17/644 (2.64%)	19
URTICARIA ^† 1	33/642 (5.14%)	49	10/644 (1.55%)	12
Vascular disorders
HOT FLUSH ^† 1	35/642 (5.45%)	37	48/644 (7.45%)	57
HYPERTENSION ^† 1	225/642 (35.05%)	354	263/644 (40.84%)	392
1 Term from vocabulary, MedDRA version 25.0 † Indicates events were collected by systematic assessment

Limitations and Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.

Results Point of Contact

Layout table for Results Point of Contact information

Name/Title:	Medical Communications
Organization:	Hoffmann-La Roche
Phone:	800-821-8590
EMail:	genentech@druginfo.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Maenpaa J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23. Erratum In: J Clin Oncol. 2021 Jul 20;39(21):2420.

Moore KN, Pignata S. Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2019 Jan 10:ijgc-2018-000071. doi: 10.1136/ijgc-2018-000071. Online ahead of print.

Layout table for additonal information

Responsible Party:	Hoffmann-La Roche
ClinicalTrials.gov Identifier:	NCT03038100
Other Study ID Numbers:	YO39523 2016-003472-52 ( EudraCT Number )
First Submitted:	January 30, 2017
First Posted:	January 31, 2017
Results First Submitted:	January 9, 2023
Results First Posted:	February 17, 2023
Last Update Posted:	February 17, 2023

To Top